BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Harbord M, Eliakim R, Bettenworth D, Karmiris K, Katsanos K, Kopylov U, Kucharzik T, Molnár T, Raine T, Sebastian S, de Sousa HT, Dignass A, Carbonnel F; for the European Crohn’s and Colitis Organisation [ECCO]. Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. Journal of Crohn's and Colitis 2017;11:769-84. [DOI: 10.1093/ecco-jcc/jjx009] [Cited by in Crossref: 492] [Cited by in F6Publishing: 414] [Article Influence: 98.4] [Reference Citation Analysis]
Number Citing Articles
1 Atreya R, Peyrin-Biroulet L, Klymenko A, Augustyn M, Bakulin I, Slankamenac D, Miheller P, Gasbarrini A, Hébuterne X, Arnesson K, Knittel T, Kowalski J, Neurath MF, Sandborn WJ, Reinisch W; CONDUCT study group. Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial. Lancet Gastroenterol Hepatol 2020;5:1063-75. [PMID: 33031757 DOI: 10.1016/S2468-1253(20)30301-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
2 Chapman TP, Gomes CF, Louis E, Colombel J, Satsangi J. De-escalation of immunomodulator and biological therapy in inflammatory bowel disease. The Lancet Gastroenterology & Hepatology 2020;5:63-79. [DOI: 10.1016/s2468-1253(19)30186-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
3 Yamamoto-Furusho JK, Sarmiento-Aguilar A, Parra-Holguín NN, Bozada-Gutiérrez KE. Evaluation of a vaccination regimen and care in relation to follow-up and treatment of patients with inflammatory bowel disease. Rev Gastroenterol Mex (Engl Ed) 2019;84:11-7. [PMID: 29605092 DOI: 10.1016/j.rgmx.2018.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Hegyi PJ, Szakács Z, Faluhelyi N, Németh BC, Bajor J, Hegyi P. Recurrent acute pancreatitis induced by 5-ASA and azathioprine in ulcerative colitis. Pancreatology 2020;20:1656-60. [DOI: 10.1016/j.pan.2020.10.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Angelidou I, Chrysanthopoulou A, Mitsios A, Arelaki S, Arampatzioglou A, Kambas K, Ritis D, Tsironidou V, Moschos I, Dalla V, Stakos D, Kouklakis G, Mitroulis I, Ritis K, Skendros P. REDD1/Autophagy Pathway Is Associated with Neutrophil-Driven IL-1β Inflammatory Response in Active Ulcerative Colitis. J I 2018;200:3950-61. [DOI: 10.4049/jimmunol.1701643] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 9.3] [Reference Citation Analysis]
6 Jain S, Ahuja V, Limdi JK. Optimal management of acute severe ulcerative colitis. Postgrad Med J. 2019;95:32-40. [PMID: 30636193 DOI: 10.1136/postgradmedj-2018-136072] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
7 Matsuoka K, Ishikawa H, Nakayama T, Honzawa Y, Maemoto A, Hirai F, Ueno F, Sato N, Susuta Y, Hibi T. Physician-patient communication affects patient satisfaction in treatment decision-making: a structural equation modelling analysis of a web-based survey in patients with ulcerative colitis. J Gastroenterol 2021;56:843-55. [PMID: 34313863 DOI: 10.1007/s00535-021-01811-1] [Reference Citation Analysis]
8 van Gennep S, de Boer NK, D'Haens GR, Löwenberg M. Thiopurine Treatment in Ulcerative Colitis: A Critical Review of the Evidence for Current Clinical Practice. Inflamm Bowel Dis 2017;24:67-77. [PMID: 29272488 DOI: 10.1093/ibd/izx025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
9 de Chambrun GP, Nachury M, Funakoshi N, Gerard R, Bismuth M, Valats JC, Panaro F, Navarro F, Desreumaux P, Pariente B, Blanc P. Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis. Eur J Gastroenterol Hepatol. 2018;30:1247-1252. [PMID: 30052539 DOI: 10.1097/meg.0000000000001223] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Calafat M, Mañosa M, Cañete F, Ricart E, Iglesias E, Calvo M, Rodríguez-Moranta F, Taxonera C, Nos P, Mesonero F, Martín-Arranz MD, Mínguez M, Gisbert JP, García-López S, de Francisco R, Gomollón F, Calvet X, Garcia-Planella E, Rivero M, Martínez-Cadilla J, Argüelles F, Arias L, Cimavilla M, Zabana Y, Domènech E; ENEIDA registry of GETECCU. Increased risk of thiopurine-related adverse events in elderly patients with IBD. Aliment Pharmacol Ther 2019;50:780-8. [PMID: 31429097 DOI: 10.1111/apt.15458] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 7.3] [Reference Citation Analysis]
11 Chen L, Yang J, Fang L, Wu W, Feng B, Shi Y, Sun M, Sun X, Liu Z. The Degree of Ulcerative Colitis Burden of Luminal Inflammation score is superior to predicting medium- to long-term prognosis in patients with active ulcerative colitis. Therap Adv Gastroenterol 2020;13:1756284820981210. [PMID: 33425012 DOI: 10.1177/1756284820981210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Calafat M, Mañosa M, Mesonero F, Guardiola J, Mínguez M, Nos P, Vera I, Taxonera C, Iglesias E, Ricart E, Gisbert JP, Calvet X, García-López S, Monfort D, Pérez Calle JL, Riestra S, Gomollón F, Garcia-Planella E, Bermejo F, Hernández V, Martín-Arranz MD, Gutiérrez A, Torres P, Cañete F, Domènech E; ENEIDA registry of GETECCU . Switching to a Second Thiopurine in Adult and Elderly Patients With Inflammatory Bowel Disease: A Nationwide Study From the ENEIDA Registry. J Crohns Colitis 2020;14:1290-8. [PMID: 32201893 DOI: 10.1093/ecco-jcc/jjaa055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
13 Marti-Aguado D, Ballester MP, Tosca J, Bosca-Watts MM, Navarro P, Anton R, Pascual I, Mora F, Minguez M. Long-term follow-up of patients treated with aminosalicylates for ulcerative colitis: Predictive factors of response: An observational case-control study. United European Gastroenterol J 2019;7:1042-50. [PMID: 31662861 DOI: 10.1177/2050640619854277] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Saifuddin A, Harris A. Tacrolimus therapy in moderate to subacute ulcerative proctocolitis: a large single-centre cohort study. Frontline Gastroenterol. 2018;9:148-153. [PMID: 29588844 DOI: 10.1136/flgastro-2017-100888] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
15 Vong C, Martin SW, Deng C, Xie R, Ito K, Su C, Sandborn WJ, Mukherjee A. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis. Clin Pharmacol Drug Dev 2021;10:229-40. [PMID: 33513294 DOI: 10.1002/cpdd.899] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Johnson CM, Linzay CD, Dassopoulos T. Maneuvering Clinical Pathways for Ulcerative Colitis. Curr Gastroenterol Rep 2019;21. [DOI: 10.1007/s11894-019-0716-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
17 Shin J, Kong SM, Kim TJ, Kim ER, Hong SN, Chang DK, Kim YH. Clinical Significance of Residual Nonrectal Inflammation in Ulcerative Colitis Patients in Clinical Remission. Gut Liver 2021;15:401-9. [PMID: 32839361 DOI: 10.5009/gnl20078] [Reference Citation Analysis]
18 Breton J, Kastl A, Hoffmann N, Rogers R, Grossman AB, Mamula P, Kelsen JR, Baldassano RN, Albenberg L. Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1586-93. [PMID: 30715364 DOI: 10.1093/ibd/izz006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
19 Halfvarson J, Cummings F, Grip O, Savoye G. Inflammatory bowel disease registries for collection of patient iron parameters in Europe. World J Gastroenterol 2018; 24(10): 1063-1071 [PMID: 29563751 DOI: 10.3748/wjg.v24.i10.1063] [Reference Citation Analysis]
20 Singh S, Proudfoot JA, Dulai PS, Jairath V, Fumery M, Xu R, Feagan BG, Sandborn WJ. No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials. Am J Gastroenterol 2018;113:1197-205. [PMID: 29925913 DOI: 10.1038/s41395-018-0144-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
21 D'Amico F, Fiorino G, Peyrin-Biroulet L, Danese S. Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing. Immunotherapy 2019;11:565-75. [PMID: 30860423 DOI: 10.2217/imt-2018-0209] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
22 Lukin D, Faleck D, Xu R, Zhang Y, Weiss A, Aniwan S, Kadire S, Tran G, Rahal M, Winters A, Chablaney S, Koliani-Pace JL, Meserve J, Campbell JP, Kochhar G, Bohm M, Varma S, Fischer M, Boland B, Singh S, Hirten R, Ungaro R, Lasch K, Shmidt E, Jairath V, Hudesman D, Chang S, Swaminath A, Shen B, Kane S, Loftus EV Jr, Sands BE, Colombel JF, Siegel CA, Sandborn WJ, Dulai PS. Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31388-4. [PMID: 33039584 DOI: 10.1016/j.cgh.2020.10.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
23 Dohos D, Hanák L, Szakács Z, Kiss S, Párniczky A, Erőss B, Pázmány P, Hegyi P, Sarlós P. Systematic review with meta-analysis: the effects of immunomodulator or biological withdrawal from mono- or combination therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2021;53:220-33. [PMID: 33249621 DOI: 10.1111/apt.16182] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
24 Vernero M, Ribaldone DG, Astegiano M, Pellicano R. Risk of incident melanoma in patients with inflammatory disease treated with anti-TNF: the Turin experience. G Ital Dermatol Venereol 2020;155:366-7. [PMID: 30249085 DOI: 10.23736/S0392-0488.18.06017-0] [Reference Citation Analysis]
25 Kariyawasam VC, Mourad FH, Mitrev N, Paramsothy S, Selinger CP, Katelaris PH, Jones B, McDonald C, Barr G, Chapman G, Cowlishaw J, Andrews J, Leong RW. Early thiopurine maintenance is associated with reduced proximal disease progression and colectomy rate in ulcerative colitis. Eur J Gastroenterol Hepatol 2021;33:1524-32. [PMID: 33731581 DOI: 10.1097/MEG.0000000000002101] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Bertani L, Bodini G, Mumolo MG, de Bortoli N, Ceccarelli L, Frazzoni L, Tapete G, Albano E, Plaz Torres MC, Bellini M, Savarino E, Savarino V, Marchi S, Costa F. Corticosteroid Treatment at Diagnosis: An Analysis of Relapses, Disease Extension, and Colectomy Rate in Ulcerative Colitis. Dig Dis Sci 2020;65:2397-402. [DOI: 10.1007/s10620-019-05959-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Fernandes SR, Pinto JSLD, Marques da Costa P, Correia L; GEDII. Disagreement Among Gastroenterologists Using the Mayo and Rutgeerts Endoscopic Scores. Inflammatory Bowel Diseases 2018;24:254-60. [DOI: 10.1093/ibd/izx066] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
28 de Simone C. The Unregulated Probiotic Market. Clinical Gastroenterology and Hepatology 2019;17:809-17. [DOI: 10.1016/j.cgh.2018.01.018] [Cited by in Crossref: 81] [Cited by in F6Publishing: 56] [Article Influence: 27.0] [Reference Citation Analysis]
29 Alhalabi M, Eddin KA, Ali F, Abbas A. SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis: A case report. Medicine (Baltimore) 2022;101:e28722. [PMID: 35089243 DOI: 10.1097/MD.0000000000028722] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Pugliese D, Guidi L, Privitera G, Bertani L, Tolusso B, Papparella LG, Maltinti S, Di Mario C, Onali S, Ceccarelli L, Rapaccini GL, Scaldaferri F, Gremese E, Gasbarrini A, Costa F, Armuzzi A. Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients. Expert Opin Biol Ther 2021;21:97-104. [PMID: 33074723 DOI: 10.1080/14712598.2020.1839045] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Czarnewski P, Parigi SM, Sorini C, Diaz OE, Das S, Gagliani N, Villablanca EJ. Conserved transcriptomic profile between mouse and human colitis allows unsupervised patient stratification. Nat Commun 2019;10:2892. [PMID: 31253778 DOI: 10.1038/s41467-019-10769-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 8.3] [Reference Citation Analysis]
32 Hvas CL, Bendix M, Dige A, Dahlerup JF, Agnholt J. Current, experimental, and future treatments in inflammatory bowel disease: a clinical review. Immunopharmacol Immunotoxicol 2018;40:446-60. [PMID: 29745777 DOI: 10.1080/08923973.2018.1469144] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
33 Matsuoka K, Watanabe M, Ohmori T, Nakajima K, Ishida T, Ishiguro Y, Kanke K, Kobayashi K, Hirai F, Watanabe K, Mizusawa H, Kishida S, Miura Y, Ohta A, Kajioka T, Hibi T, Motoya S, Maemoto A, Fujiya M, Ashida T, Goto M, Matsumoto T, Suzuki Y, Hamahata Y, Nakagawa T, Kato N, Kato J, Endo Y, Suzuki R, Matsuda K, Ohmiya N, Katsushima S, Hosomi S, Tarumi K, Watanabe C, Saito M, Yokoyama Y, Inaba T, Sakata Y, Hongo H, Shibuya T, Kawakami K, Kakuta Y, Irisawa A, Yoshimura N, Fukuda K, Shirai T, Ichikawa H, Nagata J, Suzuki T, Yokoyama K, Tomidokoro T, Kojima Y, Yamada M, Yamamoto H, Yamamoto T, Horiki N, Obata H, Inoue S, Tanaka S, Toyokawa T, Kunihiro M, Hisabe T, Ogata S, Takeshima F, Matsushima K, Matsuhashi N, Sakuraba H, Iwabuchi M, Tsuchiya A, Uchiyama K, Kanai T, Nakamura M, Yokoyama T, Hida N, Mitsuyama K, Osada T, Hiraoka S, Tsuzuki T, Masuo T, Hokari R, Kobayashi T, Saruta M, Araki M, Araki H, Shimizu M, Kikuchi M, Nishikawa T, Takedatsu H, Aoyagi K, Ochiai T, Toda N, Mizokami Y, Nagahori M, Matsueda K, Kino H, Kanamori A, Suzuki T, Sakurai T, Kudo M, Kitano A, Hisamatsu T, Kumagai S, Ninomiya T, Mori K, Yoshida S, Goto M. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Gastroenterology & Hepatology 2022;7:648-57. [DOI: 10.1016/s2468-1253(22)00022-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
34 Yalchin M, Baker AM, Graham TA, Hart A. Predicting Colorectal Cancer Occurrence in IBD. Cancers (Basel) 2021;13:2908. [PMID: 34200768 DOI: 10.3390/cancers13122908] [Reference Citation Analysis]
35 Törüner M, Akpınar H, Akyüz F, Dağlı Ü, Över Hamzaoğlu H, Tezel A, Ünsal B, Yıldırım S, Çelik AF. 2019 Expert opinion on biological treatment use in inflammatory bowel disease management. Turk J Gastroenterol 2019;30:S913-46. [PMID: 32207688 DOI: 10.5152/tjg.2019.061119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Li JR, Ling FM, Chen YD, Xu MY, Zhu LR. Treatment of acute severe ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2021; 29(2): 87-92 [DOI: 10.11569/wcjd.v29.i2.87] [Reference Citation Analysis]
37 Huguet JM, Cortés X, Bosca-Watts MM, Aguas M, Maroto N, Martí L, Amorós C, Paredes JM. Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease. World J Clin Cases 2021; 9(36): 11285-11299 [DOI: 10.12998/wjcc.v9.i36.11285] [Reference Citation Analysis]
38 Stange EF. Steroid-refractory ulcerative colitis: a critical review of national and international guideline recommendations. Z Gastroenterol 2021. [PMID: 34161990 DOI: 10.1055/a-1482-9273] [Reference Citation Analysis]
39 Casanova MJ, Chaparro M, Gisbert JP. Errors in the care of inflammatory bowel disease patients: "Errata" Study. Gastroenterol Hepatol 2020;43:233-9. [PMID: 31964522 DOI: 10.1016/j.gastrohep.2019.11.001] [Reference Citation Analysis]
40 Dobsch P, Michels B, Müller-Schilling M, Kandulski A. [Therapeutic regimens using monoclonal antibodies in gastroenterology]. Internist (Berl) 2019;60:1043-58. [PMID: 31501913 DOI: 10.1007/s00108-019-00682-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Chebli JMF, Queiroz NSF, Damião AOMC, Chebli LA, Costa MHM, Parra RS. How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician. World J Gastroenterol 2021; 27(11): 1022-1042 [PMID: 33776370 DOI: 10.3748/wjg.v27.i11.1022] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
42 Papaefthymiou A, Potamianos S, Goulas A, Doulberis M, Kountouras J, Polyzos SA. Inflammatory Bowel Disease-associated Fatty Liver Disease: the Potential Effect of Biologic Agents. J Crohns Colitis 2021:jjab212. [PMID: 34972203 DOI: 10.1093/ecco-jcc/jjab212] [Reference Citation Analysis]
43 Schreiber S, Dignass A, Peyrin-Biroulet L, Hather G, Demuth D, Mosli M, Curtis R, Khalid JM, Loftus EV Jr. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53:1048-1064. [PMID: 29869016 DOI: 10.1007/s00535-018-1480-0] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 14.3] [Reference Citation Analysis]
44 Bokemeyer B, Ghiani M, Fuchs A, Deiters B, Hardtstock F, Brandes A, Knop J, Orzechowski HD, Wilke T. Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting. Int J Colorectal Dis 2020;35:1587-98. [PMID: 32424526 DOI: 10.1007/s00384-020-03588-w] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Sahu P, Kedia S, Vuyyuru SK, Bajaj A, Markandey M, Singh N, Singh M, Kante B, Kumar P, Ranjan M, Sahni P, Panwar R, Sharma R, Das P, Makharia G, Travis SPL, Ahuja V. Randomised clinical trial: exclusive enteral nutrition versus standard of care for acute severe ulcerative colitis. Aliment Pharmacol Ther 2021;53:568-76. [PMID: 33440046 DOI: 10.1111/apt.16249] [Reference Citation Analysis]
46 Ollech JE, Dwadasi S, Rai V, Peleg N, Normatov I, Israel A, Sossenheimer PH, Christensen B, Pekow J, Dalal SR, Sakuraba A, Cohen RD, Rubin DT. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 2020;51:637-43. [DOI: 10.1111/apt.15616] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
47 Madarame A, Fukuzawa M, Yamauchi Y, Kono S, Sugimoto A, Yamaguchi H, Morise T, Koyama Y, Uchida K, Suguro M, Matsumoto T, Yasuyuki K, Kawai T, Itoi T. Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase. PLoS One 2021;16:e0255620. [PMID: 34347848 DOI: 10.1371/journal.pone.0255620] [Reference Citation Analysis]
48 Ha C, Kim ES, Kwon Y, Choe YH, Kim MJ, Lee SY. The Identification of a Novel Thiopurine S-Methyltransferase Allele, TPMT*45, in Korean Patient with Crohn's Disease. Pharmgenomics Pers Med 2020;13:665-71. [PMID: 33273844 DOI: 10.2147/PGPM.S279446] [Reference Citation Analysis]
49 Orlandini B, Dragoni G, Variola A, Massella A, Bagnoli S, Campi R, Rogai F. Clinical efficacy and safety of golimumab in biologically experienced and naive patients with active ulcerative colitis: A real-life experience from two Italian IBD centers. J Dig Dis 2018;19:468-74. [PMID: 30039533 DOI: 10.1111/1751-2980.12648] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Kato S, Ishibashi A, Kani K, Yakabi K. Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository. Digestion 2018;97:59-63. [DOI: 10.1159/000484224] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
51 Dziąbowska-Grabias K, Sztanke M, Zając P, Celejewski M, Kurek K, Szkutnicki S, Korga P, Bulikowski W, Sztanke K. Antioxidant Therapy in Inflammatory Bowel Diseases. Antioxidants (Basel) 2021;10:412. [PMID: 33803138 DOI: 10.3390/antiox10030412] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Ye BD, Travis S. Improving the quality of care for inflammatory bowel disease. Intest Res 2019;17:45-53. [PMID: 30449081 DOI: 10.5217/ir.2018.00113] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
53 Hong SN. Endoscopic Therapeutic Approach for Dysplasia in Inflammatory Bowel Disease. Clin Endosc 2017;50:437-45. [PMID: 29017293 DOI: 10.5946/ce.2017.132] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
54 Guberna L, Nyssen OP, Chaparro M, Gisbert JP. Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. J Clin Med 2021;10:2132. [PMID: 34069295 DOI: 10.3390/jcm10102132] [Reference Citation Analysis]
55 Viscido A, Papi C, Latella G, Frieri G. Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? Biologics 2019;13:23-31. [PMID: 31114154 DOI: 10.2147/BTT.S179006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
56 Holleran G, Scaldaferri F, Gasbarrini A, Currò D. Herbal medicinal products for inflammatory bowel disease: A focus on those assessed in double-blind randomised controlled trials. Phytother Res 2020;34:77-93. [PMID: 31701598 DOI: 10.1002/ptr.6517] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
57 Haga K, Shibuya T, Nomura K, Okahara K, Nomura O, Ishikawa D, Sakamoto N, Osada T, Nagahara A. Effectiveness and Nephrotoxicity of Long-Term Tacrolimus Administration in Patients with Ulcerative Colitis. J Clin Med 2020;9:E1771. [PMID: 32517388 DOI: 10.3390/jcm9061771] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
58 Honzawa Y, Yamamoto S, Okabe M, Seno H, Nakase H. Current Topics of the Mechanism of Intestinal Fibrosis in Crohn’s Disease. Immuno 2021;1:574-82. [DOI: 10.3390/immuno1040040] [Reference Citation Analysis]
59 Sicilia B, García-López S, González-Lama Y, Zabana Y, Hinojosa J, Gomollón F; Grupo Español de Trabajo de Enfermedad de Crohn., Colitis Ulcerosa o Spanish Group for Working on Crohn's Disease and Ulcerative Colitis (GETECCU). GETECCU 2020 guidelines for the treatment of ulcerative colitis. Developed using the GRADE approach. Gastroenterol Hepatol 2020;43 Suppl 1:1-57. [PMID: 32807301 DOI: 10.1016/j.gastrohep.2020.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
60 Yang QY, Ma LL, Zhang C, Lin JZ, Han L, He YN, Xie CG. Exploring the Mechanism of Indigo Naturalis in the Treatment of Ulcerative Colitis Based on TLR4/MyD88/NF-κB Signaling Pathway and Gut Microbiota. Front Pharmacol 2021;12:674416. [PMID: 34366843 DOI: 10.3389/fphar.2021.674416] [Reference Citation Analysis]
61 Parfenov AI, Knyazev OV, Babayan AF, Kagramanova AV. Low adherence to treatment is a weak link in the problems of ulcerative colitis. Terapevticheskii arkhiv 2022;93:1419-27. [DOI: 10.26442/00403660.2021.12.201172] [Reference Citation Analysis]
62 Ma C, Jeyarajah J, Guizzetti L, Parker CE, Singh S, Dulai PS, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V. Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol 2022;20:447-454.e1. [PMID: 33279779 DOI: 10.1016/j.cgh.2020.11.040] [Reference Citation Analysis]
63 Hoque S, Puenpatom A, Boccaletti S, Green C, Black CM, Roberts J, Rajkovic I, Milligan G. Treatment persistence and colectomy-free outcomes in patients with ulcerative colitis receiving golimumab or adalimumab: a UK experience. BMJ Open Gastroenterol 2020;7:e000476. [PMID: 33199269 DOI: 10.1136/bmjgast-2020-000476] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Silva NOE, de Brito BB, da Silva FAF, Santos MLC, de Melo FF. Probiotics in inflammatory bowel disease: Does it work? World J Meta-Anal 2020; 8(2): 54-66 [DOI: 10.13105/wjma.v8.i2.54] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
65 Rodríguez-lago I, Ferreiro-iglesias R, Nos P, Gisbert JP. Manejo de la colitis ulcerosa aguda grave en España: Resultados de una encuesta sobre práctica clínica. Gastroenterología y Hepatología 2019;42:90-101. [DOI: 10.1016/j.gastrohep.2018.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
66 Faelens R, Wang Z, Bouillon T, Declerck P, Ferrante M, Vermeire S, Dreesen E. Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis. Pharmaceutics 2021;13:1623. [PMID: 34683916 DOI: 10.3390/pharmaceutics13101623] [Reference Citation Analysis]
67 Gemayel NC, Rizzello E, Atanasov P, Wirth D, Borsi A. Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence. Current Medical Research and Opinion 2019;35:1911-23. [DOI: 10.1080/03007995.2019.1631058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
68 Vatn SS, Lindstrøm JC, Moen AE, Brackmann S, Tannæs TM, Olbjørn C, Bergemalm D, Keita ÅV, Gomollon F, Detlie TE, Lüders T, Kalla R, Adams A, Satsangi J, Jahnsen J, Vatn MH, Halfvarson J, Ricanek P, Nilsen H. Mucosal Gene Transcript Signatures in Treatment Naïve Inflammatory Bowel Disease: A Comparative Analysis of Disease to Symptomatic and Healthy Controls in the European IBD-Character Cohort. CEG 2022;Volume 15:5-25. [DOI: 10.2147/ceg.s343468] [Reference Citation Analysis]
69 Peyrin-Biroulet L, Sandborn WJ, Panaccione R, Domènech E, Pouillon L, Siegmund B, Danese S, Ghosh S. Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues. Therap Adv Gastroenterol 2021;14:17562848211059954. [PMID: 34917173 DOI: 10.1177/17562848211059954] [Reference Citation Analysis]
70 Harmand PO, Solassol J. Thiopurine Drugs in the Treatment of Ulcerative Colitis: Identification of a Novel Deleterious Mutation in TPMT. Genes (Basel) 2020;11:E1212. [PMID: 33081236 DOI: 10.3390/genes11101212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Akbar A, Arnott I, Kennedy NA, Nolan J, Peake S, Whiteoak SR, Probert C, Fraser A, Cheshire A, Lewis A, Sugrue K, Laird S, Scott G. Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis. Br J Hosp Med (Lond) 2021;82:1-11. [PMID: 34726945 DOI: 10.12968/hmed.2021.0399] [Reference Citation Analysis]
72 Jacobs I, Ceulemans M, Wauters L, Breynaert C, Vermeire S, Verstockt B, Vanuytsel T. Role of Eosinophils in Intestinal Inflammation and Fibrosis in Inflammatory Bowel Disease: An Overlooked Villain? Front Immunol 2021;12:754413. [PMID: 34737752 DOI: 10.3389/fimmu.2021.754413] [Reference Citation Analysis]
73 Argollo M, Fiorino G, Gilardi D, Furfaro F, Roda G, Loy L, Allocca M, Peyrin-biroulet L, Danese S. Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that? CPD 2019;25:7-12. [DOI: 10.2174/1381612825666190312113610] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
74 European Association for the Study of the Liver. Electronic address: jhepatology@easloffice.eu., European Association for the Study of the Liver. EASL Clinical Practice Guidelines on Sclerosing Cholangitis. J Hepatol 2022:S0168-8278(22)00326-9. [PMID: 35738507 DOI: 10.1016/j.jhep.2022.05.011] [Reference Citation Analysis]
75 Frias-gomes C, Torres J, Palmela C. Intestinal Ultrasound in Inflammatory Bowel Disease: A Valuable and Increasingly Important Tool. GE Port J Gastroenterol. [DOI: 10.1159/000520212] [Reference Citation Analysis]
76 Antonelli E, Torti G, Bassotti G. Inhibitors of the Janus Kinases: A New Oral Treatment Option for Ulcerative Colitis.J Clin Gastroenterol. 2019;53:635-640. [PMID: 31373941 DOI: 10.1097/MCG.0000000000001250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
77 Khan N, Pernes T, Weiss A, Trivedi C, Patel M, Xie D, Yang YX. Incidence of Infections and Malignancy Among Elderly Male Patients with IBD Exposed to Vedolizumab, Prednisone, and 5-ASA Medications: A Nationwide Retrospective Cohort Study. Adv Ther 2021;38:2586-98. [PMID: 33844132 DOI: 10.1007/s12325-021-01713-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
78 Thomas PWA, Chin PKL, Barclay ML. A nationwide survey on therapeutic drug monitoring of anti-tumour necrosis factor agents for inflammatory bowel disease. Intern Med J 2021;51:341-7. [PMID: 32043746 DOI: 10.1111/imj.14778] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
79 Bezzio C, Imperatore N, Armuzzi A, Rizzello F, Manes G, Bossa F, Calabrese E, Caprioli F, Daperno M, Mocciaro F, Orlando A, Papi C, Rispo A, Saibeni S; the Italian Group for Inflammatory Bowel Disease (IG‐IBD). Barriers to anti‐TNFalpha prescription among Italian physicians managing inflammatory bowel disease. GastroHep 2019;1:93-9. [DOI: 10.1002/ygh2.331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
80 Goodsall TM, Costello SP, Bryant RV. ABC of topical therapy in inflammatory bowel disease. JGH Open 2020;4:556-7. [PMID: 32782936 DOI: 10.1002/jgh3.12323] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
81 Argyriou K, Samuel S, Moran GW. Acetarsol in the management of mesalazine-refractory ulcerative proctitis: a tertiary-level care experience. European Journal of Gastroenterology & Hepatology 2019;31:183-6. [DOI: 10.1097/meg.0000000000001326] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
82 Cremon C, Barbaro MR, Ventura M, Barbara G. Pre- and probiotic overview. Curr Opin Pharmacol. 2018;43:87-92. [PMID: 30219638 DOI: 10.1016/j.coph.2018.08.010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 25] [Article Influence: 10.8] [Reference Citation Analysis]
83 Ylisaukko-Oja T, Puttonen M, Jokelainen J, Koivusalo M, Tamminen K, Torvinen S, Voutilainen M. Dose-escalation of adalimumab, golimumab or ustekinumab in inflammatory bowel diseases: characterization and implications in real-life clinical practice. Scand J Gastroenterol 2021;:1-9. [PMID: 34927504 DOI: 10.1080/00365521.2021.2014950] [Reference Citation Analysis]
84 Cammarota G, Ianiro G. FMT for ulcerative colitis: closer to the turning point. Nat Rev Gastroenterol Hepatol 2019;16:266-8. [PMID: 30850823 DOI: 10.1038/s41575-019-0131-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
85 Rosiou K, Ong Ming San E, Kumar A, Esquivel K, Almas S, Stokes D, Ng T, Jayasooriya N, Ranasinghe I, Pollok R, Brookes M, Selinger CP. Comparative Outcomes of Budesonide MMX versus Prednisolone for Ulcerative Colitis: Results from a British Retrospective Multi-Centre Real-World Study. J Clin Med 2021;10:4329. [PMID: 34640345 DOI: 10.3390/jcm10194329] [Reference Citation Analysis]
86 Banerjee R, Ali RAR, Wei SC, Adsul S. Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries. Gut Liver 2020;14:685-98. [PMID: 33191310 DOI: 10.5009/gnl19209] [Reference Citation Analysis]
87 Armuzzi A, DiBonaventura MD, Tarallo M, Lucas J, Bluff D, Hoskin B, Bargo D, Cappelleri JC, Quirk D, Salese L. Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. PLoS One 2020;15:e0227914. [PMID: 31945774 DOI: 10.1371/journal.pone.0227914] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
88 Bae JH, Yang DH. [Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics]. Korean J Gastroenterol 2018;71:192-5. [PMID: 29684967 DOI: 10.4166/kjg.2018.71.4.192] [Reference Citation Analysis]
89 Chaparro M, Garre A, Mesonero F, Rodríguez C, Barreiro-de Acosta M, Martínez-cadilla J, Arroyo MT, Manceñido N, Sierra-ausín M, Vera-mendoza I, Casanova MJ, Nos P, González-muñoza C, Martínez T, Boscá-watts M, Calafat M, Busquets D, Girona E, Llaó J, Martín-arranz MD, Piqueras M, Ramos L, Surís G, Bermejo F, Carbajo AY, Casas-deza D, Fernández-clotet A, García MJ, Ginard D, Gutiérrez-casbas A, Hernández L, Lucendo AJ, Márquez L, Merino-ochoa O, Rancel FJ, Taxonera C, López Sanromán A, Rubio S, Domènech E, Gisbert JP. Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry. Journal of Crohn's and Colitis 2021;15:35-42. [DOI: 10.1093/ecco-jcc/jjaa145] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
90 Rizzello F, Mazza M, Salice M, Calabrese C, Calafiore A, Campieri M, Gionchetti P. The safety of beclomethasone dipropionate in the treatment of ulcerative colitis. Expert Opinion on Drug Safety 2018;17:963-9. [DOI: 10.1080/14740338.2018.1510914] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
91 Chiu Y, Chen C, Ko C, Liao S, Yeh H, Chang C. Real‐world efficacy and safety of vedolizumab among patients with inflammatory bowel disease: A single tertiary medical center experience in Central Taiwan. Adv in Digestive Med 2021;8:40-6. [DOI: 10.1002/aid2.13188] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
92 Veny M, Garrido-Trigo A, Corraliza AM, Masamunt MC, Bassolas-Molina H, Esteller M, Arroyes M, Tristán E, Fernández-Clotet A, Ordás I, Ricart E, Esteve M, Panés J, Salas A. Dissecting Common and Unique Effects of Anti-α4β7 and Anti-Tumor Necrosis Factor Treatment in Ulcerative Colitis. J Crohns Colitis 2021;15:441-52. [PMID: 32926095 DOI: 10.1093/ecco-jcc/jjaa178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
93 Ran Z, Wu K, Matsuoka K, Jeen YT, Wei SC, Ahuja V, Chen M, Hu PJ, Andoh A, Kim HJ, Yang SK, Watanabe M, Ng SC, Hibi T, Hilmi IN, Suzuki Y, Han DS, Leung WK, Sollano J, Ooi CJ, Qian J. Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. J Gastroenterol Hepatol 2021;36:637-45. [PMID: 32672839 DOI: 10.1111/jgh.15185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Fiorino G, Danese S, Giacobazzi G, Spinelli A. Medical therapy versus surgery in moderate-to-severe ulcerative colitis. Digestive and Liver Disease 2021;53:403-8. [DOI: 10.1016/j.dld.2020.09.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
95 Seong G, Song JH, Kim JE, Kim TJ, Kim ER, Hong SN, Chang DK, Kim SH, Ha SY, Kim YH. Histologic Activity and Steroid Use History Are Risk Factors of Clinical Relapse in Ulcerative Colitis With Mayo Endoscopic Subscore of 0 or 1. Inflamm Bowel Dis 2022:izac075. [PMID: 35396998 DOI: 10.1093/ibd/izac075] [Reference Citation Analysis]
96 Gervais L, Mclean LL, Wilson ML, Cameron C, Curtis L, Garrick V, Armstrong K, Tayler R, Henderson P, Hansen R, Chalmers I, Wilson DC, Russell RK. Switching From Originator to Biosimilar Infliximab in Paediatric Inflammatory Bowel Disease Is Feasible and Uneventful. Journal of Pediatric Gastroenterology & Nutrition 2018;67:745-8. [DOI: 10.1097/mpg.0000000000002091] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
97 Catalan-Serra I, Brenna Ø. Immunotherapy in inflammatory bowel disease: Novel and emerging treatments. Hum Vaccin Immunother 2018;14:2597-611. [PMID: 29624476 DOI: 10.1080/21645515.2018.1461297] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
98 Mizuno S, Ono K, Mikami Y, Naganuma M, Fukuda T, Minami K, Masaoka T, Terada S, Yoshida T, Saigusa K, Hirahara N, Miyata H, Suda W, Hattori M, Kanai T. 5-Aminosalicylic acid intolerance is associated with a risk of adverse clinical outcomes and dysbiosis in patients with ulcerative colitis. Intest Res 2020;18:69-78. [PMID: 32013315 DOI: 10.5217/ir.2019.00084] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
99 Larsen MD, Nørgård BM, Kjeldsen J. Does Disease Activity After Induction Treatment With Biologics Predict Short-Term Outcome in Crohn's Disease and Ulcerative Colitis? Inflamm Bowel Dis 2022:izab331. [PMID: 34977919 DOI: 10.1093/ibd/izab331] [Reference Citation Analysis]
100 Fan Y, Yi W, Huang H, Mei Z, Feng Z. Efficacy of herbal medicine (Gegen Qinlian Decoction) on ulcerative colitis: A systematic review of randomized controlled trials. Medicine (Baltimore). 2019;98:e18512. [PMID: 31876740 DOI: 10.1097/md.0000000000018512] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
101 Marsal J, Barreiro-de Acosta M, Blumenstein I, Cappello M, Bazin T, Sebastian S. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease. Front Med 2022;9:897936. [DOI: 10.3389/fmed.2022.897936] [Reference Citation Analysis]
102 Haar GS, Vasudevan A, Curtain CM, van Langenberg DR. Assessing adherence to infusion-based biologic therapies in patients with inflammatory bowel disease. Res Social Adm Pharm 2021;17:1420-5. [PMID: 33129684 DOI: 10.1016/j.sapharm.2020.10.011] [Reference Citation Analysis]
103 Hinojosa Del Val J, Barreiro-de Acosta M. Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab. Gastroenterol Hepatol 2019;42:650-6. [PMID: 31635855 DOI: 10.1016/j.gastrohep.2019.08.007] [Reference Citation Analysis]
104 Hu J, Chen HW, Zhang M, Liang CM, Zhang YQ, Zhi M. Curative effect of different routes of mesalazine administration in treatment of patients with ulcerative colitis. Shijie Huaren Xiaohua Zazhi 2017; 25(36): 3203-3210 [DOI: 10.11569/wcjd.v25.i36.3203] [Reference Citation Analysis]
105 Liebert A, Wileńska A, Czuber-Dochan W, Kłopocka M. Translation and validation of the inflammatory bowel disease fatigue (IBD-F) patient self-assessment questionnaire. Prz Gastroenterol 2021;6:136-43. [PMID: 34276841 DOI: 10.5114/pg.2021.106665] [Reference Citation Analysis]
106 Fiorino G, Gilardi D, Correale C, Furfaro F, Roda G, Loy L, Argollo M, Allocca M, Peyrin-biroulet L, Danese S. Biosimilars of adalimumab: the upcoming challenge in IBD. Expert Opinion on Biological Therapy 2019;19:1023-30. [DOI: 10.1080/14712598.2019.1564033] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
107 Krugliak Cleveland N, Ollech JE, Colman RJ, Rodriquez D, Hirsch A, Cohen RD, Hanauer SB, Hart J, Hurst R, Rubin DT. Efficacy and Follow-up of Segmental or Subtotal Colectomy in Patients With Colitis-Associated Neoplasia. Clin Gastroenterol Hepatol 2019;17:205-6. [PMID: 29751167 DOI: 10.1016/j.cgh.2018.04.061] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
108 Whaley KG, Rosen MJ. Contemporary Medical Management of Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:56-66. [PMID: 29889235 DOI: 10.1093/ibd/izy208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
109 Matsuoka K, Igarashi A, Sato N, Isono Y, Gouda M, Iwasaki K, Shoji A, Hisamatsu T. Trends in Corticosteroid Prescriptions for Ulcerative Colitis and Factors Associated with Long-Term Corticosteroid Use: Analysis Using Japanese Claims Data from 2006 to 2016. J Crohns Colitis 2021;15:358-66. [PMID: 32845311 DOI: 10.1093/ecco-jcc/jjaa172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
110 Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). J Dig Dis 2021;22:298-317. [PMID: 33905603 DOI: 10.1111/1751-2980.12994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Gisbert JP, Gaffney K, Young D, Ebbers HC, Girolomoni G. Current evidence on the use of the adalimumab biosimilar SB5 (ImraldiTM): a multidisciplinary perspective. Expert Opin Biol Ther 2021;:1-13. [PMID: 34918591 DOI: 10.1080/14712598.2022.2012146] [Reference Citation Analysis]
112 Freitas M, Lima Capela T, Macedo Silva V, Arieira C, Cúrdia Gonçalves T, Dias de Castro F, Moreira MJ, Firmino-Machado J, Cotter J. Finding Predictors of Azathioprine-Induced Pancreatitis in Patients With Inflammatory Bowel Disease. Pancreas 2022;51:288-94. [PMID: 35584388 DOI: 10.1097/MPA.0000000000002012] [Reference Citation Analysis]
113 Vestergaard T, Jørgensen SMD, Christensen LA, Julsgaard M. Pregnancy outcome in four women with inflammatory bowel disease treated with budesonide MMX. Scandinavian Journal of Gastroenterology 2018;53:1459-62. [DOI: 10.1080/00365521.2018.1533583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
114 Novacek G, Gröchenig HP, Haas T, Wenzl H, Steiner P, Koch R, Feichtenschlager T, Eckhardt G, Mayer A, Kirchgatterer A, Ludwiczek O, Platzer R, Papay P, Gartner J, Fuchssteiner H, Miehsler W, Peters PG, Reicht G, Vogelsang H, Dejaco C, Waldhör T; Austrian IBD Study Group (ATISG). Diagnostic delay in patients with inflammatory bowel disease in Austria. Wien Klin Wochenschr 2019;131:104-12. [PMID: 30715607 DOI: 10.1007/s00508-019-1451-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
115 Fernández-clotet A, Castro-poceiro J, Panés J. Tofacitinib for the treatment of ulcerative colitis. Expert Review of Clinical Immunology 2018;14:881-92. [DOI: 10.1080/1744666x.2018.1532291] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
116 Cronin J, Moore S, Lenihan N, O'Shea M, Woods N. The non-drug costs associated with the administration of an intravenous biologic treatment in the hospital setting. Ir J Med Sci 2019;188:821-34. [PMID: 30467804 DOI: 10.1007/s11845-018-1925-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
117 Lenti MV, Armuzzi A, Castiglione F, Fantini MC, Fiorino G, Orlando A, Pugliese D, Rizzello F, Vecchi M, Di Sabatino A. Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign. Digestive and Liver Disease 2020;52:44-50. [DOI: 10.1016/j.dld.2019.09.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
118 Lee KM. [Monitoring Disease Activity: How and When?]. Korean J Gastroenterol 2018;71:69-73. [PMID: 29471603 DOI: 10.4166/kjg.2018.71.2.69] [Reference Citation Analysis]
119 Strohl M, Gonczi L, Kurt Z, Bessissow T, L Lakatos P. Quality of care in inflammatory bowel diseases: What is the best way to better outcomes? World J Gastroenterol 2018; 24(22): 2363-2372 [PMID: 29904243 DOI: 10.3748/wjg.v24.i22.2363] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
120 Rivière P, Laharie D, Marteau P. Concise Commentary: Second Line Is Not Second Best-Continuing Validity of the Oxford Criteria in the Management of Acute Severe Ulcerative Colitis. Dig Dis Sci 2020;65:581-2. [PMID: 31489565 DOI: 10.1007/s10620-019-05788-z] [Reference Citation Analysis]
121 Lubrano E, Luchetti MM, Benfaremo D, Mauro D, Ciccia F, Perrotta FM. Inflammatory bowel disease manifestations in spondyloarthritis: considerations for the clinician. Expert Rev Clin Immunol 2021;17:1199-209. [PMID: 34622735 DOI: 10.1080/1744666X.2021.1991315] [Reference Citation Analysis]
122 Caruso ML, Di Pinto F, Ignazzi A, Coletta S, Valentini AM, Cavalcanti E, De Michele F. Increased nerve twigs in small intestinal mucosa with programmed cell death-ligand 1 and somatostatin receptor type 2A expression in recurrent Crohn disease: A case report. Medicine (Baltimore) 2018;97:e13492. [PMID: 30544444 DOI: 10.1097/MD.0000000000013492] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
123 Argollo MC, Kotze PG, Spinelli A, Gomes TN, Danese S. The impact of biologics in surgical outcomes in ulcerative colitis. Best Practice & Research Clinical Gastroenterology 2018;32-33:79-87. [DOI: 10.1016/j.bpg.2018.05.014] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
124 Bonovas S, Pantavou K, Evripidou D, Bastiampillai AJ, Nikolopoulos GK, Peyrin-Biroulet L, Danese S. Safety of biological therapies in ulcerative colitis: An umbrella review of meta-analyses. Best Pract Res Clin Gastroenterol 2018;32-33:43-7. [PMID: 30060938 DOI: 10.1016/j.bpg.2018.05.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
125 Teixeira FV, Damião AOMC, Kotze PG. TOFACITINIB IN THE MANAGEMENT OF ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF AND ANTI-INTEGRIN THERAPIES. Arq Gastroenterol 2018;55:198-200. [PMID: 30043874 DOI: 10.1590/S0004-2803.201800000-36] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
126 Sands BE, Armuzzi A, Marshall JK, Lindsay JO, Sandborn WJ, Danese S, Panés J, Bressler B, Colombel JF, Lawendy N, Maller E, Zhang H, Chan G, Salese L, Tsilkos K, Marren A, Su C. Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open. Aliment Pharmacol Ther 2020;51:271-80. [PMID: 31660640 DOI: 10.1111/apt.15555] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
127 Bonovas S, Nikolopoulos GK, Piovani D, González-Lorenzo M, Pantavou K, Lytras T, Peyrin-Biroulet L, Danese S. Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. Br J Clin Pharmacol 2019;85:2244-54. [PMID: 31269287 DOI: 10.1111/bcp.14051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
128 Verstockt B, Bressler B, Martinez-Lozano H, McGovern D, Silverberg MS. Time to Revisit Disease Classification in Inflammatory Bowel Disease: Is the Current Classification of Inflammatory Bowel Disease Good Enough for Optimal Clinical Management? Gastroenterology 2022;162:1370-82. [PMID: 34995534 DOI: 10.1053/j.gastro.2021.12.246] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
129 Ribaldone DG. Inflammatory bowel disease and pancreatic diseases. Minerva Gastroenterol Dietol 2020;66. [DOI: 10.23736/s1121-421x.20.02668-9] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
130 Ben Nessib D, Ferjani H, Maatallah K, Rahmouni S, Kaffel D, Hamdi W. Update on therapeutic management of spondyloarthritis associated with inflammatory bowel disease. Clin Rheumatol 2020;39:3543-53. [PMID: 32424656 DOI: 10.1007/s10067-020-05136-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
131 Coelho MR, Romi MD, Ferreira DMTP, Zaltman C, Soares-Mota M. The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials. Nutrients. 2020;12. [PMID: 32751776 DOI: 10.3390/nu12082296] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
132 Magro F, Estevinho MM, Dias CC, Correia L, Lago P, Ministro P, Portela F, Feakins R, Danese S, Peyrin-Biroulet L. Clinical, Endoscopic and Histological Outcomes in Induction of Moderate-to-Severe Ulcerative Colitis: A Systematic Review with Meta-Analysis. J Crohns Colitis 2021;15:551-66. [PMID: 32898223 DOI: 10.1093/ecco-jcc/jjaa176] [Reference Citation Analysis]
133 Sands BE, Cheifetz AS, Nduaka CI, Quirk D, Wang W, Maller E, Friedman GS, Su C, Higgins PDR. The Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis. J Crohns Colitis 2019;13:1217-26. [PMID: 30879034 DOI: 10.1093/ecco-jcc/jjz038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
134 Bröms G, Söderling J, Sachs MC, Halfvarson J, Myrelid P, Ludvigsson JF, Everhov ÅH, Olén O; SWIBREG study group. Capturing biologic treatment for IBD in the Swedish Prescribed Drug Register and the Swedish National Patient Register - a validation study. Scand J Gastroenterol 2021;56:410-21. [PMID: 33632044 DOI: 10.1080/00365521.2021.1884894] [Reference Citation Analysis]
135 Dulai PS, Peyrin-Biroulet L, Danese S, Sands BE, Dignass A, Turner D, Mantzaris G, Schölmerich J, Mary JY, Reinisch W, Sandborn WJ. Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases. Gastroenterology 2019;157:1032-1043.e1. [PMID: 31228441 DOI: 10.1053/j.gastro.2019.06.018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
136 Wang Z, Dreesen E. Therapeutic drug monitoring of anti-tumor necrosis factor agents: lessons learned and remaining issues. Current Opinion in Pharmacology 2020;55:53-9. [DOI: 10.1016/j.coph.2020.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
137 Khan R, Li J, Scaffidi MA, Gimpaya N, Pivetta B, Grover SC. Conflicts of Interest in Inflammatory Bowel Disease Articles on UpToDate. J Can Assoc Gastroenterol 2021;4:10-4. [PMID: 33644671 DOI: 10.1093/jcag/gwz030] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
138 Tahvilian N, Masoodi M, Faghihi Kashani A, Vafa M, Aryaeian N, Heydarian A, Hosseini A, Moradi N, Farsi F. Effects of saffron supplementation on oxidative/antioxidant status and severity of disease in ulcerative colitis patients: A randomized, double-blind, placebo-controlled study. Phytother Res 2021;35:946-53. [PMID: 33015869 DOI: 10.1002/ptr.6848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
139 Salice M, Rizzello F, Calabrese C, Calandrini L, Gionchetti P. A current overview of corticosteroid use in active ulcerative colitis. Expert Rev Gastroenterol Hepatol 2019;13:557-61. [PMID: 30947569 DOI: 10.1080/17474124.2019.1604219] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
140 Danese S, Vermeire S, Zhou W, Pangan AL, Siffledeen J, Greenbloom S, Hébuterne X, D'haens G, Nakase H, Panés J, Higgins PDR, Juillerat P, Lindsay JO, Loftus EV, Sandborn WJ, Reinisch W, Chen M, Sanchez Gonzalez Y, Huang B, Xie W, Liu J, Weinreich MA, Panaccione R. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. The Lancet 2022. [DOI: 10.1016/s0140-6736(22)00581-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
141 Ballester MP, Marti-aguado D, Fullana M, Bosca-watts MM, Tosca J, Romero E, Sanchez A, Navarro-cortes P, Anton R, Mora F, Minguez M. Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system. Int J Colorectal Dis 2019;34:1053-9. [DOI: 10.1007/s00384-019-03271-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
142 Zhang Y, Wang J, Hou D, Yan S, Dang S. To assess the effective and safety of berberine hydrochloride in ulcerative colitis: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e23482. [PMID: 33285751 DOI: 10.1097/MD.0000000000023482] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
143 Gherardi A, Roze S, Kuijvenhoven J, Ghatnekar O, Yip Sonderegger YL. Budesonide with multi-matrix technology as second-line treatment for ulcerative colitis: evaluation of long-term cost-effectiveness in the Netherlands. J Med Econ 2018;21:869-77. [PMID: 29857775 DOI: 10.1080/13696998.2018.1484371] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
144 Ma C, Guizzetti L, Cipriano LE, Parker CE, Nguyen TM, Gregor JC, Chande N, Feagan BG, Jairath V. Systematic review with meta-analysis: high prevalence and cost of continued aminosalicylate use in patients with ulcerative colitis escalated to immunosuppressive and biological therapies. Aliment Pharmacol Ther 2019;49:364-74. [PMID: 30569460 DOI: 10.1111/apt.15090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
145 Wyant T, Yang L, Lirio RA, Rosario M. Vedolizumab Immunogenicity With Long-Term or Interrupted Treatment of Patients With Inflammatory Bowel Disease. J Clin Pharmacol 2021;61:1174-81. [PMID: 33908636 DOI: 10.1002/jcph.1877] [Reference Citation Analysis]
146 Bokemeyer B, Picker N, Wilke T, Rosin L, Patel H. Inadequate Response, Treatment Patterns, Health Care Utilization, and Associated Costs in Patients With Ulcerative Colitis: Retrospective Cohort Study Based on German Claims Data. Inflamm Bowel Dis 2022:izab330. [PMID: 35134912 DOI: 10.1093/ibd/izab330] [Reference Citation Analysis]
147 Hagelund LM, Elkjær Stallknecht S, Jensen HH. Quality of life and patient preferences among Danish patients with ulcerative colitis - results from a survey study. Curr Med Res Opin 2020;36:771-9. [PMID: 31944145 DOI: 10.1080/03007995.2020.1716704] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
148 Lin H, Bai Z, Wu Q, Chu G, Zhang Y, Guo X, Qi X. Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study. Front Public Health 2022;10:851295. [PMID: 35359771 DOI: 10.3389/fpubh.2022.851295] [Reference Citation Analysis]
149 Grosen A, Nersting J, Bungum M, Christensen LA, Schmiegelow K, Spanò M, Julsgaard M, Cordelli E, Leter G, Larsen PB, Hvas CL, Kelsen J. Sperm DNA Integrity is Unaffected by Thiopurine Treatment in Men With Inflammatory Bowel Disease. J Crohns Colitis 2019;13:3-11. [PMID: 29917107 DOI: 10.1093/ecco-jcc/jjy086] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
150 Sebastian S, Lisle J, Subramanian S, Dhar A, Shenoy A, Limdi J, Butterworth J, Allen PB, Samuel S, Moran G, Shenderey R, Parkes G, Raine T, Lobo AJ, Kennedy NA. Practice pattern variability in the management of acute severe colitis: a UK provider survey. Frontline Gastroenterol 2020;11:272-9. [PMID: 32587670 DOI: 10.1136/flgastro-2019-101277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
151 Abdel-Wahab BA, Alkahtani SA, Alqahtani AA, Hassanein EHM. Umbelliferone ameliorates ulcerative colitis induced by acetic acid via modulation of TLR4/NF-κB-p65/iNOS and SIRT1/PPARγ signaling pathways in rats. Environ Sci Pollut Res Int 2022;29:37644-59. [PMID: 35066822 DOI: 10.1007/s11356-021-18252-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Anisdahl K, Svatun Lirhus S, Medhus AW, Moum B, Melberg HO, Høivik ML. First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study. Scand J Gastroenterol 2021;:1-6. [PMID: 34320885 DOI: 10.1080/00365521.2021.1955147] [Reference Citation Analysis]
153 Grazie ML, Bagnoli S, Dragoni G, Caini S, Annese V, Innocenti T, Deiana S, Manetti N, Milani S, Galli A, Milla M. Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study. Ann Gastroenterol 2021;34:370-7. [PMID: 33948062 DOI: 10.20524/aog.2021.0584] [Reference Citation Analysis]
154 Viscido A, Valvano M, Stefanelli G, Capannolo A, Castellini C, Onori E, Ciccone A, Vernia F, Latella G. Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis. BMC Gastroenterol 2022;22:92. [PMID: 35240984 DOI: 10.1186/s12876-022-02157-5] [Reference Citation Analysis]
155 Mukherjee A, Tsuchiwata S, Nicholas T, Cook JA, Modesto I, Su C, D'Haens GR, Sandborn WJ. Exposure-Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies. Clin Pharmacol Ther 2022;112:90-100. [PMID: 35380740 DOI: 10.1002/cpt.2601] [Reference Citation Analysis]
156 Thomson P, Núñez P, Quera R, Bay C. Gastrointestinal microbiome, what is behind faecal microbiota transplantation? New Microbes New Infect 2021;42:100898. [PMID: 34168881 DOI: 10.1016/j.nmni.2021.100898] [Reference Citation Analysis]
157 Le Baut G, Kirchgesner J, Amiot A, Lefevre JH, Chafai N, Landman C, Nion I, Bourrier A, Delattre C, Martineau C, Sokol H, Seksik P, Nguyen Y, Marion Y, Lebreton G, Carbonnel F, Viennot S, Beaugerie L; Saint Antoine IBD Network. A Scoring System to Determine Patients' Risk of Colectomy Within 1 Year After Hospital Admission for Acute Severe Ulcerative Colitis. Clin Gastroenterol Hepatol 2021;19:1602-1610.e1. [PMID: 31927106 DOI: 10.1016/j.cgh.2019.12.036] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
158 Nishio M, Ishii Y, Hashimoto Y, Otake H, Ogashiwa T, Tsuda S, Yasuhara H, Saigusa Y, Kimura H, Maeda S, Kunisaki R. Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis. Scand J Gastroenterol 2018;53:1236-44. [PMID: 30353757 DOI: 10.1080/00365521.2018.1511825] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
159 Moutinho BD, Baima JP, Rigo FF, Saad-Hossne R, Rodrigues J, Romeiro FG, Sassaki LY. Fecal microbiota transplantation in refractory ulcerative colitis - a case report. J Int Med Res 2019;47:1072-9. [PMID: 30632438 DOI: 10.1177/0300060518821790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
160 Arieira C, Dias de Castro F, Cúrdia Gonçalves T, Moreira MJ, Cotter J. Combination therapy in inflammatory bowel disease patients: do we need to maximize the dose of azathioprine? Scandinavian Journal of Gastroenterology 2020;55:920-3. [DOI: 10.1080/00365521.2020.1792543] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
161 Becker HEF, Penders J, Jonkers DMAE. Microbial Metabolism of Inflammatory Bowel Disease Drugs: Current Evidence and Clinical Implementations. Gastroenterology 2021:S0016-5085(21)03488-0. [PMID: 34508777 DOI: 10.1053/j.gastro.2021.07.050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
162 Miller C, Emmanuel A, Zarate-Lopez N, Taylor S, Bloom S. Constipation in ulcerative colitis: pathophysiology and practical management. Frontline Gastroenterol 2021;12:493-9. [PMID: 34712467 DOI: 10.1136/flgastro-2020-101566] [Reference Citation Analysis]
163 Lin L, Zhou G, Chen P, Wang Y, Han J, Chen M, He Y, Zhang S. Which long noncoding RNAs and circular RNAs contribute to inflammatory bowel disease? Cell Death Dis 2020;11:456. [PMID: 32541691 DOI: 10.1038/s41419-020-2657-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
164 Nijakowski K, Rutkowski R, Eder P, Korybalska K, Witowski J, Surdacka A. Changes in Salivary Parameters of Oral Immunity after Biologic Therapy for Inflammatory Bowel Disease. Life (Basel) 2021;11:1409. [PMID: 34947940 DOI: 10.3390/life11121409] [Reference Citation Analysis]
165 Uchiyama K, Takagi T, Mizushima K, Asaeda K, Kajiwara M, Kashiwagi S, Minagawa Y, Hotta Y, Tanaka M, Inoue K, Dohi O, Okayama T, Yoshida N, Katada K, Kamada K, Ishikawa T, Yasuda H, Konishi H, Kishimoto M, Naito Y, Itoh Y. Investigation on the Inhibitory Effect of Wnt-5a on Colonic Mucosal Inflammation in Patients with Ulcerative Colitis. Dig Dis Sci 2022. [PMID: 35590045 DOI: 10.1007/s10620-022-07537-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
166 Jackson B, De Cruz P. Algorithms to facilitate shared decision-making for the management of mild-to-moderate ulcerative colitis. Expert Rev Gastroenterol Hepatol 2018;12:1079-100. [PMID: 30284911 DOI: 10.1080/17474124.2018.1530109] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
167 Rahmi G, Coron E, Perrod G, Levy M, Moreau J, Moussata D, Perez-Cuadrado-Robles E, Chupin A, Quénéhervé L, Bourreille A, Marchal A, Cellier C, Peyrin-Biroulet L. Probe-based Confocal Laser Endomicroscopy for In Vivo Assessment of Histological Healing in Ulcerative Colitis: Development and Validation of the ENHANCE Index. J Crohns Colitis 2021;15:994-9. [PMID: 33336249 DOI: 10.1093/ecco-jcc/jjaa255] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
168 Reinglas J, Gonczi L, Kurt Z, Bessissow T, Lakatos PL. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. World J Gastroenterol 2018; 24(32): 3567-3582 [PMID: 30166855 DOI: 10.3748/wjg.v24.i32.3567] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 20] [Article Influence: 6.3] [Reference Citation Analysis]
169 Wang YJ, Li QM, Zha XQ, Luo JP. Intervention and potential mechanism of non-starch polysaccharides from natural resources on ulcerative colitis: A review. Int J Biol Macromol 2022;210:545-64. [PMID: 35513106 DOI: 10.1016/j.ijbiomac.2022.04.208] [Reference Citation Analysis]
170 Trigo-vicente C, Gimeno-ballester V, García-lópez S, López-del Val A. Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis. Int J Clin Pharm 2018;40:1411-9. [DOI: 10.1007/s11096-018-0743-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
171 Paschos P, Katsoula A, Giouleme O, Sarigianni M, Liakos A, Athanasiadou E, Bekiari E, Tsapas A. Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis. Ann Gastroenterol 2018;31:572-82. [PMID: 30174394 DOI: 10.20524/aog.2018.0276] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
172 Machado MGM, Scarim CB, de Andrade CR, dos Santos JL, Chin CM. Synthesis and anti-inflammatory intestinal activity of new glucocorticoid derivatives. Med Chem Res 2020;29:206-16. [DOI: 10.1007/s00044-019-02474-7] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
173 Ciccocioppo R, Mengoli C, Betti E, Comolli G, Cassaniti I, Piralla A, Kruzliak P, Caprnda M, Pozzi L, Corazza GR, Di Sabatino A, Baldanti F. Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis. Clin Exp Med 2021;21:379-88. [PMID: 33772380 DOI: 10.1007/s10238-021-00702-2] [Reference Citation Analysis]
174 Caron B, Sandborn WJ, Panaccione R, Schreiber S, Hart A, Solitano V, Danese S, Peyrin-Biroulet L. Efficacy of pharmacological agents for ulcerative proctitis: a systematic literature review. J Crohns Colitis 2021:jjab218. [PMID: 34850857 DOI: 10.1093/ecco-jcc/jjab218] [Reference Citation Analysis]
175 Jhaj G, Kopplin LJ. Ocular features of the HLA-B27-positive seronegative spondyloarthropathies. Current Opinion in Ophthalmology 2018;29:552-7. [DOI: 10.1097/icu.0000000000000525] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
176 St Clair-Jones A, Prignano F, Goncalves J, Paul M, Sewerin P. Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review. Rheumatol Ther 2020;7:741-57. [PMID: 33206343 DOI: 10.1007/s40744-020-00245-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
177 Cai X, Wang X, He M, Wang Y, Lan M, Zhao Y, Gao F. Colon-targeted delivery of tacrolimus using pH-responsive polymeric nanoparticles for murine colitis therapy. Int J Pharm 2021;606:120836. [PMID: 34217824 DOI: 10.1016/j.ijpharm.2021.120836] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
178 Gisbert JP, Chaparro M. Acute severe ulcerative colitis: State of the art treatment. Best Pract Res Clin Gastroenterol 2018;32-33:59-69. [PMID: 30060940 DOI: 10.1016/j.bpg.2018.05.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
179 Maconi G, Camatta D, Cannatelli R, Ferretti F, Carvalhas Gabrielli A, Ardizzone S. Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety. Ther Clin Risk Manag 2021;17:285-92. [PMID: 33854320 DOI: 10.2147/TCRM.S263835] [Reference Citation Analysis]
180 Szandruk-Bender M, Rutkowska M, Merwid-Ląd A, Wiatrak B, Szeląg A, Dzimira S, Sobieszczańska B, Krzystek-Korpacka M, Kucharska AZ, Matuszewska A, Nowak B, Piórecki N, Duda-Madej A, Walczuk U, Turniak M, Bednarz-Misa I, Sozański T. Cornelian Cherry Iridoid-Polyphenolic Extract Improves Mucosal Epithelial Barrier Integrity in Rat Experimental Colitis and Exerts Antimicrobial and Antiadhesive Activities In Vitro. Oxid Med Cell Longev 2020;2020:7697851. [PMID: 33299531 DOI: 10.1155/2020/7697851] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
181 Solitano V, D'Amico F, Fiorino G, Peyrin-Biroulet L, Danese S. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice. Expert Rev Clin Immunol 2020;16:1019-28. [PMID: 32954893 DOI: 10.1080/1744666X.2021.1826311] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
182 Magro F, Lopes S, Silva M, Coelho R, Portela F, Branquinho D, Correia L, Fernandes S, Cravo M, Caldeira P, Tavares de Sousa H, Patita M, Lago P, Ramos J, Afonso J, Redondo I, Machado P, Philip G, Lopes J, Carneiro F. Soluble human Suppression of Tumorigenicity 2 is associated with endoscopic activity in patients with moderate-to-severe ulcerative colitis treated with golimumab. Therap Adv Gastroenterol 2019;12:1756284819869141. [PMID: 31516554 DOI: 10.1177/1756284819869141] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
183 Miehlke S, Acosta MB, Bouma G, Carpio D, Magro F, Moreels T, Probert C. Oral budesonide in gastrointestinal and liver disease: A practical guide for the clinician: Optimising therapy with budesonide. Journal of Gastroenterology and Hepatology 2018;33:1574-81. [DOI: 10.1111/jgh.14151] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
184 Xu G, Sun Y, He H, Xue Q, Liu Y, Dong L. Effect of TrkB-PLC/IP3 pathway on intestinal inflammatory factors and enterocyte apoptosis in mice with colitis. Acta Biochim Biophys Sin (Shanghai) 2020;52:675-82. [PMID: 32445466 DOI: 10.1093/abbs/gmaa044] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
185 Schreiber S, Ben-Horin S, Leszczyszyn J, Dudkowiak R, Lahat A, Gawdis-Wojnarska B, Pukitis A, Horynski M, Farkas K, Kierkus J, Kowalski M, Lee SJ, Kim SH, Suh JH, Kim MR, Lee SG, Ye BD, Reinisch W. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. Gastroenterology 2021;160:2340-53. [PMID: 33676969 DOI: 10.1053/j.gastro.2021.02.068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
186 Mazza S, Soro S, Verga MC, Elvo B, Ferretti F, Cereatti F, Drago A, Grassia R. Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders. World J Hepatol 2021; 13(12): 1828-1849 [DOI: 10.4254/wjh.v13.i12.1828] [Reference Citation Analysis]
187 de Chambrun GP, Danese S, Peyrin-biroulet L. Time to include patients with ulcerative proctitis in clinical trials. The Lancet Gastroenterology & Hepatology 2019;4:900-2. [DOI: 10.1016/s2468-1253(19)30341-3] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
188 Troncone E, Marafini I, Del Vecchio Blanco G, Di Grazia A, Monteleone G. Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors. Clin Exp Gastroenterol 2020;13:131-9. [PMID: 32440190 DOI: 10.2147/CEG.S208020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
189 Mañosa M, Chaparro M, Juan A, Aràjol C, Alfaro I, Mínguez M, Velayos B, Benítez J, Mesonero F, Sicilia B, Zabana Y, Villoria A, Gisbert J, Domènech E; on behalf of the ENEIDA registry by GETECCU. Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic Cancers. Am J Gastroenterol 2019;114:771-6. [DOI: 10.14309/ajg.0000000000000210] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
190 Zhang W, Chao X, Wu JQ, Ma XB, Yang YL, Wu Y, Lin JC. Exploring the Potential Mechanism of Guchang Zhixie Wan for Treating Ulcerative Colitis by Comprehensive Network Pharmacological Approaches and Molecular Docking Validation as Well as Cell Experiments. Chem Biodivers 2021;18:e2000810. [PMID: 33251769 DOI: 10.1002/cbdv.202000810] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
191 Rezk MF, Pieper B. Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review. Adv Ther 2020;37:3732-45. [PMID: 32740789 DOI: 10.1007/s12325-020-01437-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
192 Sagami S, Kobayashi T, Aihara K, Umeda M, Odajima K, Morikubo H, Asonuma K, Miyatani Y, Fukuda T, Matsubayashi M, Kiyohara H, Nakano M, Hibi T. Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis. Aliment Pharmacol Ther 2022;55:1320-9. [PMID: 35218038 DOI: 10.1111/apt.16817] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
193 Nigam GB, Nayeemuddin S, Kontopantelis E, Hayee B, Limdi JK. UK National Survey of Gastroenterologists' attitudes and barriers toward therapeutic drug monitoring of anti-TNF therapy in inflammatory bowel disease. Frontline Gastroenterol 2021;12:22-9. [PMID: 33493247 DOI: 10.1136/flgastro-2019-101372] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
194 Gisbert JP, Chaparro M. Are there reliable predictive factors of nonresponse to aminosalicylates in patients with ulcerative colitis? United European Gastroenterol J 2019;7:997-8. [PMID: 31662857 DOI: 10.1177/2050640619861891] [Reference Citation Analysis]
195 Aggeletopoulou I, Konstantakis C, Assimakopoulos SF, Triantos C. The role of the gut microbiota in the treatment of inflammatory bowel diseases. Microb Pathog 2019;137:103774. [PMID: 31586663 DOI: 10.1016/j.micpath.2019.103774] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
196 Barberio B, Segal JP, Quraishi MN, Black CJ, Savarino EV, Ford AC. Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis. J Crohns Colitis 2021;15:1184-96. [PMID: 33433562 DOI: 10.1093/ecco-jcc/jjab010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
197 Nash P, Kerschbaumer A, Dörner T, Dougados M, Fleischmann RM, Geissler K, McInnes I, Pope JE, van der Heijde D, Stoffer-Marx M, Takeuchi T, Trauner M, Winthrop KL, de Wit M, Aletaha D, Baraliakos X, Boehncke WH, Emery P, Isaacs JD, Kremer J, Lee EB, Maksymowych WP, Voshaar M, Tam LS, Tanaka Y, van den Bosch F, Westhovens R, Xavier R, Smolen JS. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis 2021;80:71-87. [PMID: 33158881 DOI: 10.1136/annrheumdis-2020-218398] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]
198 Pellino G, Keller DS, Sampietro GM, Annese V, Carvello M, Celentano V, Coco C, Colombo F, Cracco N, Di Candido F, Franceschi M, Laureti S, Mattioli G, Pio L, Sciaudone G, Sica G, Villanacci V, Zinicola R, Leone S, Danese S, Spinelli A, Delaini G, Selvaggi F;  the Italian Society of Colorectal Surgery (SICCR). Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management. Tech Coloproctol. 2020;24:105-126. [PMID: 31983044 DOI: 10.1007/s10151-019-02145-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
199 Strik AS, Wang YC, Ruff LE, Yashar W, Messmer BT, Mould DR. Individualized Dosing of Therapeutic Monoclonal Antibodies-a Changing Treatment Paradigm? AAPS J 2018;20:99. [PMID: 30187153 DOI: 10.1208/s12248-018-0257-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
200 da Silva LM, de Souza P, Jaouni SKA, Harakeh S, Golbabapour S, de Andrade SF. Propolis and Its Potential to Treat Gastrointestinal Disorders. Evid Based Complement Alternat Med 2018;2018:2035820. [PMID: 29736177 DOI: 10.1155/2018/2035820] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
201 Berends SE, Strik AS, Löwenberg M, D'Haens GR, Mathôt RAA. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. Clin Pharmacokinet 2019;58:15-37. [PMID: 29752633 DOI: 10.1007/s40262-018-0676-z] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
202 Escribano-Vazquez U, Beimfohr C, Bellet D, Thomas M, Zimmermann K, Langella P, Cherbuy C. Symbioflor2® Escherichia coli Genotypes Enhance Ileal and Colonic Gene Expression Associated with Mucosal Defense in Gnotobiotic Mice. Microorganisms 2020;8:E512. [PMID: 32260205 DOI: 10.3390/microorganisms8040512] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
203 Chu TPC, Grainge MJ, Card TR. The risk of venous thromboembolism during and after hospitalisation in patients with inflammatory bowel disease activity. Aliment Pharmacol Ther 2018;48:1099-108. [PMID: 30294897 DOI: 10.1111/apt.15010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
204 Zhang AF, Miao YL. Strategies for remission induction of inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2017; 25(33): 2938-2944 [DOI: 10.11569/wcjd.v25.i33.2938] [Reference Citation Analysis]
205 Weng MT, Tung CC, Chang YT, Leong YL, Wang YT, Wong JM, Wei SC. Trends of Medication Usage and Associated Outcomes for Taiwanese Patients with Inflammatory Bowel Disease from 2001 to 2015. J Clin Med 2018;7:E394. [PMID: 30373275 DOI: 10.3390/jcm7110394] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
206 Baumgart DC, Misery L, Naeyaert S, Taylor PC. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities? Front Pharmacol 2019;10:279. [PMID: 30983996 DOI: 10.3389/fphar.2019.00279] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 14.7] [Reference Citation Analysis]
207 Danese S, D'Amico F, Bonovas S, Peyrin-Biroulet L. Positioning Tofacitinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. Inflamm Bowel Dis 2018;24:2106-12. [PMID: 29697791 DOI: 10.1093/ibd/izy076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
208 Schauer C, Avery V, Seleq S, Garg P, Wang MTM, Chieng M, Rowan C, Sekra A, Lane M, Walmsley R. A comparison of intravenous methylprednisolone and hydrocortisone for the treatment of acute inflammatory bowel disease. J Gastroenterol Hepatol 2021. [PMID: 33939853 DOI: 10.1111/jgh.15535] [Reference Citation Analysis]
209 Fragoulis GE, Liava C, Daoussis D, Akriviadis E, Garyfallos A, Dimitroulas T. Inflammatory bowel diseases and spondyloarthropathies: From pathogenesis to treatment. World J Gastroenterol 2019; 25(18): 2162-2176 [PMID: 31143068 DOI: 10.3748/wjg.v25.i18.2162] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 35] [Article Influence: 15.3] [Reference Citation Analysis]
210 Noviello D, Mager R, Roda G, Borroni RG, Fiorino G, Vetrano S. The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges. Front Immunol 2021;12:611256. [PMID: 34079536 DOI: 10.3389/fimmu.2021.611256] [Reference Citation Analysis]
211 Caldeira LF, Borba HH, Tonin FS, Wiens A, Fernandez-Llimos F, Pontarolo R. Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis. PLoS One 2020;15:e0238910. [PMID: 32946509 DOI: 10.1371/journal.pone.0238910] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
212 Ackermann A, Çapcı A, Buchfelder M, Tsogoeva SB, Savaskan N. Chemical hybridization of sulfasalazine and dihydroartemisinin promotes brain tumor cell death. Sci Rep 2021;11:20766. [PMID: 34675351 DOI: 10.1038/s41598-021-99960-z] [Reference Citation Analysis]
213 Kobayashi T, Udagawa E, Uda A, Hibi T, Hisamatsu T. Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis. J Gastroenterol Hepatol 2020;35:225-32. [PMID: 31397010 DOI: 10.1111/jgh.14825] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
214 Wang Z, Mu W, Li P, Liu G, Yang J. Anti-inflammatory activity of ortho-trifluoromethoxy-substituted 4-piperidione-containing mono-carbonyl curcumin derivatives in vitro and in vivo. Eur J Pharm Sci 2021;160:105756. [PMID: 33588045 DOI: 10.1016/j.ejps.2021.105756] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
215 Ito A, Murasugi S, Omori T, Nakamura S, Tokushige K. Relationship between mucosal healing by tacrolimus and relapse of refractory ulcerative colitis: a retrospective study. BMC Gastroenterol 2020;20:203. [PMID: 32590945 DOI: 10.1186/s12876-020-01317-9] [Reference Citation Analysis]
216 Panaccione R, Abreu MT, Lazariciu I, Mundayat R, Lawendy N, Salese L, Woolcott JC, Sands BE, Chaparro M. Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open-label, long-term extension study, OCTAVE open. Aliment Pharmacol Ther 2022;55:1534-44. [PMID: 35246988 DOI: 10.1111/apt.16848] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
217 . UEG Week 2020 Oral Presentations. United European Gastroenterol j 2020;8:8-142. [DOI: 10.1177/2050640620927344] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
218 Stevens TW, Gecse K, Turner JR, de Hertogh G, Rubin DT, D'Haens GR. Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31128-9. [PMID: 32801008 DOI: 10.1016/j.cgh.2020.08.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
219 Ferrante M, Sabino J. Efficacy of JAK inhibitors in Ulcerative Colitis. J Crohns Colitis 2020;14:S737-45. [PMID: 31879750 DOI: 10.1093/ecco-jcc/jjz202] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
220 Taxonera C, de Andrés-Nogales F, García-López S, Sánchez-Guerrero A, Menchén B, Peral C, Cábez A, Gómez S, López-Ibáñez de Aldecoa A, Casado MÁ, Menchén L. Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain. Expert Rev Pharmacoecon Outcomes Res 2021;:1-11. [PMID: 33615953 DOI: 10.1080/14737167.2021.1880324] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
221 Okabayashi S, Yamazaki H, Tominaga K, Miura M, Sagami S, Matsuoka K, Yamaguchi Y, Noake T, Ozeki K, Miyazaki R, Kamano T, Fukuda T, Yoshioka K, Ando K, Fukuzawa M, Andoh A, Yamamoto Y, Hibi T, Kobayashi T; IBD Terakoya Group. Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalised patients with older onset: a multicentre cohort study. Aliment Pharmacol Ther 2022;55:1569-80. [PMID: 35274323 DOI: 10.1111/apt.16865] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
222 Faye AS, Hung KW, Cheng K, Blackett JW, Mckenney AS, Pont AR, Li J, Lawlor G, Lebwohl B, Freedberg DE. Minor Hematochezia Decreases Use of Venous Thromboembolism Prophylaxis in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;. [PMID: 31689354 DOI: 10.1093/ibd/izz269] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
223 Chiorean MV, Allegretti JR, Sharma PP, Chastek B, Salese L, Bell EJ, Peterson-brandt J, Cappelleri JC, Guo X, Khan N. Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02215-y] [Reference Citation Analysis]
224 Pugliese N, Roda G, Peyrin-biroulet L, Danese S. Emerging therapies for the treatment of ulcerative colitis. Expert Opinion on Emerging Drugs 2020;25:71-9. [DOI: 10.1080/14728214.2020.1737009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
225 Fiorino G, Allocca M, Correale C, Roda G, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Danese S. Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block. Expert Opin Biol Ther 2020;20:421-7. [PMID: 32027523 DOI: 10.1080/14712598.2020.1727437] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
226 Eronen H, Ilus T, Jussila A, Huhtala H, Collin P, Oksanen P. Long-term outcome of patients with acute ulcerative colitis after first course of intravenous corticosteroids. Scand J Gastroenterol 2021;56:234-8. [PMID: 33496198 DOI: 10.1080/00365521.2020.1867892] [Reference Citation Analysis]
227 Doherty G, Katsanos KH, Burisch J, Allez M, Papamichael K, Stallmach A, Mao R, Berset IP, Gisbert JP, Sebastian S, Kierkus J, Lopetuso L, Szymanska E, Louis E. European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease. J Crohns Colitis. 2018;12:17-31. [PMID: 28981623 DOI: 10.1093/ecco-jcc/jjx101] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 17.8] [Reference Citation Analysis]
228 Wilson A, Choi B, Sey M, Ponich T, Beaton M, Kim RB. High infliximab trough concentrations are associated with sustained histologic remission in inflammatory bowel disease: a prospective cohort study. BMC Gastroenterol 2021;21:77. [PMID: 33602145 DOI: 10.1186/s12876-021-01650-7] [Reference Citation Analysis]
229 Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.Dtsch Arztebl Int. 2020;117:564-574. [PMID: 33148393 DOI: 10.3238/arztebl.2020.0564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
230 Bezzio C, Manes G, Bini F, Pellegrini L, Saibeni S. Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds. Gut 2021;70:623-4. [PMID: 32554621 DOI: 10.1136/gutjnl-2020-321760] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 27.0] [Reference Citation Analysis]
231 Lopetuso LR, Ianiro G, Allegretti JR, Bibbò S, Gasbarrini A, Scaldaferri F, Cammarota G. Fecal transplantation for ulcerative colitis: current evidence and future applications. Expert Opin Biol Ther 2020;20:343-51. [PMID: 32083498 DOI: 10.1080/14712598.2020.1733964] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
232 Gonzalez-vivo M, Lund Tiirikainen MK, Andreu M, Fernandez-clotet A, López-garcía A, Murciano Gonzalo F, Abril Rodriguez L, de Jesús-gil C, Ruiz-romeu E, Sans-de San Nicolàs L, Santamaria-babí LF, Márquez-mosquera L. Memory T Cell Subpopulations as Early Predictors of Remission to Vedolizumab in Ulcerative Colitis. Front Med 2022;9:837294. [DOI: 10.3389/fmed.2022.837294] [Reference Citation Analysis]
233 Lu MJ, Qiu XY, Mao XQ, Li XT, Zhang HJ. Systematic review with meta-analysis: thiopurines decrease the risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2018;47:318-31. [DOI: 10.1111/apt.14436] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
234 Kolehmainen S, Lepistö A, Färkkilä M. Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016. Scand J Gastroenterol 2019;54:707-11. [PMID: 31136207 DOI: 10.1080/00365521.2019.1620326] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
235 Kuo CJ, Le PH, Tai WC, Wu KL, Yen HH, Yen CW, Tung SY, Chung CS, Su MY, Chiu CT. The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study. J Formos Med Assoc 2021:S0929-6646(21)00532-5. [PMID: 34924273 DOI: 10.1016/j.jfma.2021.11.012] [Reference Citation Analysis]
236 Feagan BG, Schreiber S, Wolf DC, Axler JL, Kaviya A, James A, Curtis RI, Geransar P, Stallmach A, Ehehalt R, Bokemeyer B, Khalid JM, O'Byrne S. Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:1028-35. [PMID: 30365009 DOI: 10.1093/ibd/izy323] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
237 Hanauer S, Sandborn WJ, Colombel JF, Vermeire S, Petersson J, Kligys K, Zhou Q, Lazar A, Reinisch W. Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials. J Crohns Colitis 2019;13:1227-33. [PMID: 30726897 DOI: 10.1093/ecco-jcc/jjz031] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
238 Eriksson C, Rundquist S, Cao Y, Montgomery S, Halfvarson J. Impact of thiopurines on the natural history and surgical outcome of ulcerative colitis: a cohort study. Gut 2019;68:623-32. [PMID: 29618498 DOI: 10.1136/gutjnl-2017-315521] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
239 Ribaldone DG, Vernero M, Caviglia GP. Targeting IL-10, ZO-1 gene expression and IL-6/STAT-3 trans-signalling by a combination of atorvastatin and mesalazine to enhance anti-inflammatory effects and attenuate progression of oxazolone-induced colitis. Fundam Clin Pharmacol 2021;35:141-2. [PMID: 33289917 DOI: 10.1111/fcp.12638] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
240 Zhu X, Chao K, Li M, Xie W, Zheng H, Zhang JX, Hu PJ, Huang M, Gao X, Wang XD. Nucleoside diphosphate-linked moiety X-type motif 15 R139C genotypes impact 6-thioguanine nucleotide cut-off levels to predict thiopurine-induced leukopenia in Crohn’s disease patients. World J Gastroenterol 2019; 25(38): 5850-5861 [PMID: 31636477 DOI: 10.3748/wjg.v25.i38.5850] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
241 Queiroz NSF, Barros LL, Azevedo MFC, Oba J, Sobrado CW, Carlos AS, Milani LR, Sipahi AM, Damião AOMC. Management of inflammatory bowel disease patients in the COVID-19 pandemic era: a Brazilian tertiary referral center guidance. Clinics (Sao Paulo) 2020;75:e1909. [PMID: 32321117 DOI: 10.6061/clinics/2020/e1909] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
242 Bertani L, Rossari F, Barberio B, Demarzo MG, Tapete G, Albano E, Baiano Svizzero G, Ceccarelli L, Mumolo MG, Brombin C, de Bortoli N, Bellini M, Marchi S, Bodini G, Savarino E, Costa F. Novel Prognostic Biomarkers of Mucosal Healing in Ulcerative Colitis Patients Treated With Anti-TNF: Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio. Inflamm Bowel Dis. 2020;26:1579-1587. [PMID: 32232392 DOI: 10.1093/ibd/izaa062] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
243 Kakimoto K, Matsuura M, Fukuchi T, Hongo H, Kimura T, Aoyama N, Okuda Y, Aomatsu K, Kamata N, Yokoyama Y, Mizuno C, Inoue T, Miyazaki T, Nakamura S, Higuchi K, Nakase H. Exploratory Study of the Effectiveness of Granulocyte and Monocyte Adsorptive Apheresis Before Initiation of Steroids in Patients With Active Ulcerative Colitis (EXPECT Study): A Multicenter Prospective Clinical Trial. Crohns Colitis 360 2020;2:otaa073. [PMID: 34192247 DOI: 10.1093/crocol/otaa073] [Reference Citation Analysis]
244 Chibbar R, Moss AC. Mesalamine in the Initial Therapy of Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:689-704. [PMID: 33121689 DOI: 10.1016/j.gtc.2020.07.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
245 Danese S, Fiorino G, Peyrin-biroulet L. Positioning Therapies in Ulcerative Colitis. Clinical Gastroenterology and Hepatology 2020;18:1280-1290.e1. [DOI: 10.1016/j.cgh.2020.01.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
246 Sandborn WJ, Colombel JF, Panaccione R, Dulai PS, Rosario M, Cao C, Barocas M, Lasch K. Deep Remission With Vedolizumab in Patients With Moderately to Severely Active Ulcerative Colitis: A GEMINI 1 post hoc Analysis. J Crohns Colitis 2019;13:172-81. [PMID: 30285104 DOI: 10.1093/ecco-jcc/jjy149] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
247 Fellermann K, Schiefke I, Rácz I, Derova J, Jonaitis L, Wehrum S, Nacak T, Greinwald R. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1). United European Gastroenterol J 2020;8:1186-95. [PMID: 33028169 DOI: 10.1177/2050640620962632] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
248 Barberio B, Zingone F, D'Incà R, Rovigo L, Bertani L, Bodini G, Ghisa M, Gubbiotti A, Massimi D, Lorenzon G, Savarino EV. Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study. Clin Transl Gastroenterol 2020;11:e00177. [PMID: 32677808 DOI: 10.14309/ctg.0000000000000177] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
249 Vermeire S, Su C, Lawendy N, Kobayashi T, Sandborn WJ, Rubin DT, Modesto I, Gardiner S, Kulisek N, Zhang H, Wang W, Panés J. Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial. J Crohns Colitis 2021;15:1130-41. [PMID: 33290538 DOI: 10.1093/ecco-jcc/jjaa249] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
250 Holleran G, Lopetuso L, Petito V, Graziani C, Ianiro G, McNamara D, Gasbarrini A, Scaldaferri F. The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease. Int J Mol Sci. 2017;18. [PMID: 28934123 DOI: 10.3390/ijms18102020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
251 Hindryckx P, Novak G. Can we move directly from 5-ASA to a biologic agent in ulcerative colitis? Best Pract Res Clin Gastroenterol 2018;32-33:9-15. [PMID: 30060944 DOI: 10.1016/j.bpg.2018.05.004] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
252 Calafat M, Mañosa M, Cañete F, Domènech E. Clinical Considerations Regarding the Use of Thiopurines in Older Patients with Inflammatory Bowel Disease. Drugs Aging 2021;38:193-203. [PMID: 33438138 DOI: 10.1007/s40266-020-00832-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 Pineton de Chambrun G, Tassy B, Kollen L, Dufour G, Valats J, Bismuth M, Funakoshi N, Panaro F, Blanc P. Refractory ulcerative proctitis: How to treat it? Best Practice & Research Clinical Gastroenterology 2018;32-33:49-57. [DOI: 10.1016/j.bpg.2018.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
254 Kovacs G, Sipeki N, Suga B, Tornai T, Fechner K, Norman GL, Shums Z, Antal-Szalmas P, Papp M. Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients. PLoS One 2018;13:e0194166. [PMID: 29590158 DOI: 10.1371/journal.pone.0194166] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
255 Gupta V, Mohsen W, Chapman TP, Satsangi J. Predicting Outcome in Acute Severe Colitis-Controversies in Clinical Practice in 2021. J Crohns Colitis 2021;15:1211-21. [PMID: 33388777 DOI: 10.1093/ecco-jcc/jjaa265] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
256 Bezzio C, Festa S, Zerboni G, Papi C, Manes G, Saibeni S. A safety evaluation of budesonide MMX for the treatment of ulcerative colitis. Expert Opinion on Drug Safety 2018;17:437-44. [DOI: 10.1080/14740338.2018.1442432] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
257 Solitano V, D'Amico F, Fiorino G, Paridaens K, Peyrin-Biroulet L, Danese S. Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis. J Clin Med 2020;9:E2905. [PMID: 32911840 DOI: 10.3390/jcm9092905] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
258 Sicilia B, Arias L, Hontoria G, García N, Badia E, Gomollón F. Are Steroids Still Useful in Immunosuppressed Patients With Inflammatory Bowel Disease? A Retrospective, Population-Based Study. Front Med (Lausanne) 2021;8:651685. [PMID: 34249960 DOI: 10.3389/fmed.2021.651685] [Reference Citation Analysis]
259 Rosiou K, Selinger CP. Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians. Intern Emerg Med 2021;16:1433-42. [PMID: 33754227 DOI: 10.1007/s11739-021-02704-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
260 Chaparro M, Garre A, Ricart E, Iglesias-Flores E, Taxonera C, Domènech E, Gisbert JP; ENEIDA study group. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU. Aliment Pharmacol Ther 2019;49:419-28. [PMID: 30637837 DOI: 10.1111/apt.15114] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
261 Kruis W, Neshta V, Pesegova M, Alekseeva O, Andreev P, Datsenko O, Levchenko O, Abdulkhakov S, Lozynskyy Y, Mostovoy Y, Soloviev K, Dorofeyev AE, Vieth M, Stiess M, Greinwald R, Mohrbacher R, Siegmund B. Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis. Clin Gastroenterol Hepatol 2019; 17: 98-106. e4. [PMID: 29702300 DOI: 10.1016/j.cgh.2018.04.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
262 Abdullah I, Alhendi G, Alhadab A, Alasfour H, Shehab M. Gastroenterologists Adherence to Tumor Necrosis Factor Antagonist Combination Therapy in Inflammatory Bowel Disease. Front Med (Lausanne) 2021;8:725512. [PMID: 34660635 DOI: 10.3389/fmed.2021.725512] [Reference Citation Analysis]
263 Ribaldone DG, Vernero M, Saracco GM, Pellicano R, Finocchiaro F, Caviglia GP, Astegiano M. The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets. Scand J Gastroenterol 2018;53:141-6. [PMID: 29228844 DOI: 10.1080/00365521.2017.1405070] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
264 de Vries JHM, Dijkhuizen M, Tap P, Witteman BJM. Patient's Dietary Beliefs and Behaviours in Inflammatory Bowel Disease. Dig Dis 2019;37:131-9. [PMID: 30391940 DOI: 10.1159/000494022] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
265 Bonovas S, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2018;47:454-465. [PMID: 29205421 DOI: 10.1111/apt.14449] [Cited by in Crossref: 75] [Cited by in F6Publishing: 67] [Article Influence: 15.0] [Reference Citation Analysis]
266 Sedano R, Jairath V, Ma C; IBD Trial Design Group. Design of Clinical Trials for Mild to Moderate Ulcerative Colitis. Gastroenterology 2022;162:1005-18. [PMID: 34998800 DOI: 10.1053/j.gastro.2021.12.284] [Reference Citation Analysis]
267 Peyrottes A, Seksik P, Doré J, Marteau P. The Microbiome in IBD. In: Sheng Ding N, De Cruz P, editors. Biomarkers in Inflammatory Bowel Diseases. Cham: Springer International Publishing; 2019. pp. 293-301. [DOI: 10.1007/978-3-030-11446-6_24] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
268 Sedano R, Quera R, Simian D, Yarur AJ. An approach to acute severe ulcerative colitis. Expert Rev Gastroenterol Hepatol 2019;13:943-55. [PMID: 31648574 DOI: 10.1080/17474124.2019.1681974] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
269 Zhou Z, Cao J, Liu X, Li M. Evidence for the butyrate metabolism as key pathway improving ulcerative colitis in both pediatric and adult patients. Bioengineered 2021;12:8309-24. [PMID: 34592880 DOI: 10.1080/21655979.2021.1985815] [Reference Citation Analysis]
270 Sandborn WJ, Baert F, Danese S, Krznarić Ž, Kobayashi T, Yao X, Chen J, Rosario M, Bhatia S, Kisfalvi K, D'Haens G, Vermeire S. Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology 2020;158:562-572.e12. [PMID: 31470005 DOI: 10.1053/j.gastro.2019.08.027] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 12.3] [Reference Citation Analysis]
271 Scribano ML, Papi C, Costa F, Bortoli A, Bortoluzzi F, Buscarini E, Cappello M, Caserta L, Cortelezzi C, Ferronato A, Manguso F, Mazzuoli S, Orzes N, Kohn A; AIGO IBD Study Group. Management of ulcerative colitis in a real-life setting: An Italian multicenter, prospective, observational AIGO study. Dig Liver Dis 2019;51:346-51. [PMID: 30195815 DOI: 10.1016/j.dld.2018.08.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
272 Pellino G, Keller DS, Sampietro GM, Angriman I, Carvello M, Celentano V, Colombo F, Di Candido F, Laureti S, Luglio G, Poggioli G, Rottoli M, Scaringi S, Sciaudone G, Sica G, Sofo L, Leone S, Danese S, Spinelli A, Delaini G, Selvaggi F; Italian Society of Colorectal Surgery SICCR. Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn's disease. Tech Coloproctol 2020;24:421-48. [PMID: 32172396 DOI: 10.1007/s10151-020-02183-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
273 Gareb B, Posthumus S, Beugeling M, Koopmans P, Touw DJ, Dijkstra G, Kosterink JGW, Frijlink HW. Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process. Pharmaceutics 2019;11:E428. [PMID: 31450748 DOI: 10.3390/pharmaceutics11090428] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
274 Pellet G, Stefanescu C, Carbonnel F, Peyrin-Biroulet L, Roblin X, Allimant C, Nachury M, Nancey S, Filippi J, Altwegg R, Brixi H, Fotsing G, de Rosamel L, Shili S, Laharie D; Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif. Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis. Clin Gastroenterol Hepatol 2019;17:494-501. [PMID: 30213584 DOI: 10.1016/j.cgh.2018.08.081] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
275 Guiotto C, Italia A, Lavagna A, Rigazio C, Cosimato M, Ercole E, Mendolaro M, Rocca R, Daperno M. Switching from infliximab originator to a first biosimilar is safe and effective. Results of a case-control study with drug levels and antibodies evaluation. Digestive and Liver Disease 2019;51:1117-22. [DOI: 10.1016/j.dld.2019.05.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
276 Fischer S, Neurath MF. Precision Medicine in Inflammatory Bowel Diseases. Clin Pharmacol Ther 2017;102:623-32. [DOI: 10.1002/cpt.793] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
277 Kvarme H, Fjellanger R, Bondevik C, Astor MC, Barrett T, Haugen O, Storebråten G, Karliczek A, Vaagbø G, Sande Leikanger I, Tveit KS, Engjom T, von Volkmann HL. A young male with epitheliolysis in the small bowel and colon. Scand J Gastroenterol 2020;55:631-3. [PMID: 32393134 DOI: 10.1080/00365521.2020.1760344] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
278 Costello SP, Day A, Yao CK, Bryant RV. Faecal microbiota transplantation (FMT) with dietary therapy for acute severe ulcerative colitis. BMJ Case Rep 2020;13:e233135. [PMID: 32843418 DOI: 10.1136/bcr-2019-233135] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
279 Shibuya T, Haga K, Kamei M, Okahara K, Ito S, Takahashi M, Nomura O, Murakami T, Makino M, Kodani T, Ishikawa D, Sakamoto N, Osada T, Ogihara T, Watanabe S, Nagahara A. Successful remission of ulcerative colitis flare-up during pregnancy with adsorptive granulomonocytapheresis plus tacrolimus. Intest Res. 2018;16:484-488. [PMID: 30090048 DOI: 10.5217/ir.2018.16.3.484] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
280 Zeng Z, Mukherjee A, Zhang H. From Genetics to Epigenetics, Roles of Epigenetics in Inflammatory Bowel Disease. Front Genet. 2019;10:1017. [PMID: 31737035 DOI: 10.3389/fgene.2019.01017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
281 Manta R, Zullo A, Telesca DA, Castellani D, Germani U, Reggiani Bonetti L, Conigliaro R, Galloro G. Endoscopic Submucosal Dissection for Visible Dysplasia Treatment in Ulcerative Colitis Patients: Cases Series and Systematic Review of Literature. J Crohns Colitis 2021;15:165-8. [PMID: 32710744 DOI: 10.1093/ecco-jcc/jjaa158] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
282 Rodríguez-Lago I, Benítez JM, Sempere L, Sáez-González E, Barreiro-de Acosta M, de Zárate JO, Cabriada JL. The combination of granulocyte-monocyte apheresis and vedolizumab: A new treatment option for ulcerative colitis? J Clin Apher 2019;34:680-5. [PMID: 31518013 DOI: 10.1002/jca.21746] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
283 Magro F, Estevinho MM. Moving from efficacy to effectiveness: budesonide multimatrix in ulcerative colitis. United European Gastroenterol J 2019;7:1153-5. [PMID: 31700627 DOI: 10.1177/2050640619878588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
284 Holvoet T, Lobaton T, Hindryckx P. Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions. Clin Exp Gastroenterol 2021;14:71-81. [PMID: 33727846 DOI: 10.2147/CEG.S197719] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
285 Rogler G, Scharl M, Spalinger M, Yilmaz B, Zaugg M, Hersberger M, Schreiner P, Biedermann L, Herfarth H. Diet and Inflammatory Bowel Disease: What Quality Standards Should Be Applied in Clinical and Laboratory Studies? Mol Nutr Food Res 2021;65:e2000514. [PMID: 33433954 DOI: 10.1002/mnfr.202000514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
286 Alsoud D, Verstockt B, Fiocchi C, Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol 2021;6:589-95. [PMID: 34019798 DOI: 10.1016/S2468-1253(21)00065-0] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
287 Fenu E, Lukyanov V, Acs A, Radu X, Stypa S, Fischer A, Marshall JK, Oppe M. Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada. PharmacoEconomics Open. [DOI: 10.1007/s41669-022-00331-9] [Reference Citation Analysis]
288 Dias T, Santos A, Santos RM, Carvalho A. Recurrent mesalazine-induced myopericarditis in a patient with ulcerative colitis. BMJ Case Rep 2019;12:e228037. [PMID: 30709886 DOI: 10.1136/bcr-2018-228037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
289 Naganuma M. Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis. J Gastroenterol 2020;55:1013-22. [PMID: 32778960 DOI: 10.1007/s00535-020-01713-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
290 Bower JAJ, O'Flynn L, Kakad R, Aldulaimi D. Effect of inflammatory bowel disease treatments on patients with diabetes mellitus. World J Diabetes 2021; 12(8): 1248-1254 [PMID: 34512890 DOI: 10.4239/wjd.v12.i8.1248] [Reference Citation Analysis]
291 Solitano V, D'Amico F, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Early Intervention in Ulcerative Colitis: Ready for Prime Time? J Clin Med 2020;9:E2646. [PMID: 32823997 DOI: 10.3390/jcm9082646] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
292 Louis E, Paridaens K, Al Awadhi S, Begun J, Cheon JH, Dignass AU, Magro F, Márquez JR, Moschen AR, Narula N, Rydzewska G, Freddi MJ, Travis SP. Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis. BMJ Open Gastroenterol 2022;9:e000853. [DOI: 10.1136/bmjgast-2021-000853] [Reference Citation Analysis]
293 Wu X, Liang TY, Wang Z, Chen G. The role of hyperbaric oxygen therapy in inflammatory bowel disease: a narrative review. Med Gas Res 2021;11:66-71. [PMID: 33818446 DOI: 10.4103/2045-9912.311497] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
294 Xu Y, Qiao YQ, Li HY, Zhou M, Cai CW, Shen J, Ran ZH. NUDT15 genotyping during azathioprine treatment in patients with inflammatory bowel disease: implications for a dose-optimization strategy. Gastroenterol Rep (Oxf) 2020;8:437-44. [PMID: 33442476 DOI: 10.1093/gastro/goaa021] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
295 Shi G, Wang D, Xue Z, Zhou X, Fang Y, Feng S, Zhao L. The amelioration of ulcerative colitis induced by Dinitrobenzenesulfonic acid with Radix Hedysari. J Food Biochem 2020;:e13421. [PMID: 32776340 DOI: 10.1111/jfbc.13421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
296 Dulai PS, Jairath V. Acute severe ulcerative colitis: latest evidence and therapeutic implications. Ther Adv Chronic Dis. 2018;9:65-72. [PMID: 29387331 DOI: 10.1177/2040622317742095] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
297 de Jong ME, Smits LJT, van Ruijven B, den Broeder N, Russel MGVM, Römkens TEH, West RL, Jansen JM, Hoentjen F. Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients. Journal of Crohn's and Colitis 2020;14:888-95. [DOI: 10.1093/ecco-jcc/jjaa012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
298 Vavricka SR, Greuter T, Cohen BL, Reinisch W, Steinwurz F, Fellmann M, Guo X, Lawendy N, Paulissen J, Peyrin-biroulet L. Corticosteroid-free efficacy and safety outcomes in patients receiving tofacitinib in the OCTAVE Sustain maintenance study. Therap Adv Gastroenterol 2022;15:175628482210908. [DOI: 10.1177/17562848221090834] [Reference Citation Analysis]
299 Szemes K, Soós A, Hegyi P, Farkas N, Erős A, Erőss B, Mezősi E, Szakács Z, Márta K, Sarlós P. Comparable Long-Term Outcomes of Cyclosporine and Infliximab in Patients With Steroid-Refractory Acute Severe Ulcerative Colitis: A Meta-Analysis. Front Med (Lausanne) 2019;6:338. [PMID: 32039218 DOI: 10.3389/fmed.2019.00338] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
300 Gajendran M, Loganathan P, Jimenez G, Catinella AP, Ng N, Umapathy C, Ziade N, Hashash JG. A comprehensive review and update on ulcerative colitis. Dis Mon. 2019;65:100851. [PMID: 30837080 DOI: 10.1016/j.disamonth.2019.02.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 16.7] [Reference Citation Analysis]
301 Kotze PG, Steinwurz F, Francisconi C, Zaltman C, Pinheiro M, Salese L, Ponce de Leon D. Review of the epidemiology and burden of ulcerative colitis in Latin America. Therap Adv Gastroenterol 2020;13:1756284820931739. [PMID: 32695230 DOI: 10.1177/1756284820931739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
302 Kobayashi T, Siegmund B, Le Berre C, Wei SC, Ferrante M, Shen B, Bernstein CN, Danese S, Peyrin-Biroulet L, Hibi T. Ulcerative colitis.Nat Rev Dis Primers. 2020;6:74. [PMID: 32913180 DOI: 10.1038/s41572-020-0205-x] [Cited by in Crossref: 52] [Cited by in F6Publishing: 55] [Article Influence: 26.0] [Reference Citation Analysis]
303 Høivik ML, Buer LCT, Cvancarova M, Warren DJ, Bolstad N, Moum BA, Medhus AW. Switching from originator to biosimilar infliximab – real world data of a prospective 18 months follow-up of a single-centre IBD population. Scandinavian Journal of Gastroenterology 2018;53:692-9. [DOI: 10.1080/00365521.2018.1463391] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
304 D'Amico F, Danese S, Peyrin-Biroulet L. Vedolizumab and etrolizumab for ulcerative colitis: twins or simple cousins? Expert Opin Biol Ther 2020;20:353-61. [PMID: 31951748 DOI: 10.1080/14712598.2020.1717465] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
305 Sassaki LY, Miszputen SJ, Kaiser Junior RL, Catapani WR, Bafutto M, Scotton AS, Zaltman C, Baima JP, Ramos HS, Faria MAG, Gonçalves CD, Guimaraes IM, Flores C, Amarante HMBS, Nones RB, Parente JML, Lima MM, Chebli JM, Ferrari MLA, Campos JF, Sanna MGP, Ramos O, Parra RS, da Rocha JJR, Feres O, Feitosa MR, Caratin RF, Senra JT, Santana GO. Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil. World J Gastroenterol 2021; 27(23): 3396-3412 [PMID: 34163120 DOI: 10.3748/wjg.v27.i23.3396] [Reference Citation Analysis]
306 Nakase H, Sato N, Mizuno N, Ikawa Y. The influence of cytokines on the complex pathology of ulcerative colitis. Autoimmun Rev 2021;:103017. [PMID: 34902606 DOI: 10.1016/j.autrev.2021.103017] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
307 Maconi G, Mezzina N, Landi S, Grillo S, Bezzio C, Bosani M, Pastorelli L, Dell'Era A, Chibbar R, Carmagnola S, Molteni P, Cassinotti A, Massari A, Ardizzone S. Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience. United European Gastroenterol J 2019;7:1164-70. [PMID: 31700629 DOI: 10.1177/2050640619864257] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
308 Paridaens K, Fullarton JR, Travis SPL. Efficacy and safety of oral Pentasa (prolonged-release mesalazine) in mild-to-moderate ulcerative colitis: a systematic review and meta-analysis. Curr Med Res Opin 2021;37:1891-900. [PMID: 34404286 DOI: 10.1080/03007995.2021.1968813] [Reference Citation Analysis]
309 Ferretti F, Cannatelli R, Monico MC, Maconi G, Ardizzone S. An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis. J Clin Med 2022;11:2302. [PMID: 35566428 DOI: 10.3390/jcm11092302] [Reference Citation Analysis]
310 Sáez-gonzález E, Aguas M, Huguet JM, Nos P, Beltrán B. Combination therapy with cytapheresis plus vedolizumab in a corticosteroid-dependent patient with ulcerative colitis and previous ANTI-TNF-α drug failure. Digestive and Liver Disease 2018;50:415-7. [DOI: 10.1016/j.dld.2018.01.124] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
311 Vermeire S, Chiorean M, Panés J, Peyrin-Biroulet L, Zhang J, Sands BE, Lazin K, Klassen P, Naik SU, Cabell CH, Sandborn WJ. Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study. J Crohns Colitis 2021;15:950-9. [PMID: 33475734 DOI: 10.1093/ecco-jcc/jjab016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
312 Nissen LHC, Derikx LAAP, Jacobs AME, van Herpen CM, Kievit W, Verhoeven R, van den Broek E, Bekers E, van den Heuvel T, Pierik M, Rahamat-langendoen J, Takes RP, Melchers WJG, Nagtegaal ID, Hoentjen F, de Jonge EEC, Natte R, Nijhuis EWP, Peutz-kootstra C, Roelofs JJTH, Willems SM, Willig AP, van Bodegraven AA, Tan ACITL, Meeuse JJ, van der Meulen–de Jong AE, Oldenburg B, Loffeld BCAJ, Durfeld BM, van der Woude CJ, Cahen DL, D’haens G, Janik D, Mares WGM, Gilissen LPL, Wolters FL, Dijkstra G, Erkelens GW, Tang TJ, Breumelhof R, Smalbraak HJT, Thijs JC, Voskuil JH, Kuyvenhoven JP, Vecht J, Rijk MCM, Janssen JM, Sarneel JT, Tjhie-wensing JWM, Lai JYL, Vlasveld LT, Oostenbrug LE, Gerretsen M, Van Herwaarden MA, Mahmmod N, Russel MGVM, Grubben MJAL, Vu MK, Verhulst ML, Dewint P, Stokkers PCF, Bus PJ, Wismans PJ, van der Haeck PWE, Stuyt RJL, Zeijen RNM, Dahlmans RPM, Vandebosch S, Romkens TEH, Moolenaar W, ten Hove WR, Boot H, van der Linde K, Wahab P, de Boer SY, Thurnau K, Thijs WJ, Josemanders DFGM, West RL, Pierik MJ, Depla ACTM, Keulen ETP, de Boer WA, Naber AHJ, Vermeijden JR, Mallant-hent RC, Beukers R, Ter Borg PCJ, Halet ECR, Bruin KF, Linskens RK, Bruins Slot W; The Dutch Initiative on Crohn and Colitis (ICC), Dutch Head and Neck Society, PALGA group, IBD/HNC group. Risk Factors and Clinical Outcomes of Head and Neck Cancer in Inflammatory Bowel Disease: A Nationwide Cohort Study. Inflammatory Bowel Diseases 2018;24:2015-26. [DOI: 10.1093/ibd/izy096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
313 Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastro 2019;17:435-48. [DOI: 10.1007/s11938-019-00249-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
314 Barrett K, Saxena S, Pollok R. Using corticosteroids appropriately in inflammatory bowel disease: a guide for primary care. Br J Gen Pract 2018;68:497-8. [PMID: 30262630 DOI: 10.3399/bjgp18X699341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
315 Tripathi K, Dong J, Mishkin BF, Feuerstein JD. Patient Preference and Adherence to Aminosalicylates for the Treatment of Ulcerative Colitis. Clin Exp Gastroenterol 2021;14:343-51. [PMID: 34511961 DOI: 10.2147/CEG.S237653] [Reference Citation Analysis]
316 Wu B, Tong J, Ran Z. Tacrolimus Therapy in Steroid-Refractory Ulcerative Colitis: A Review. Inflamm Bowel Dis. 2020;26:24-32. [PMID: 30980713 DOI: 10.1093/ibd/izz068] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
317 Magro F, Cordeiro G, Dias AM, Estevinho MM. Inflammatory Bowel Disease - Non-biological treatment. Pharmacol Res 2020;160:105075. [PMID: 32653651 DOI: 10.1016/j.phrs.2020.105075] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
318 Varma S, Hu J, Mehta A, Song Y, Park A, Zhi M, Hutfless S. Initial medical and surgical management of inflammatory bowel disease in the biologic era: A comparison between the United States and China. JGH Open 2019;3:234-41. [PMID: 31276042 DOI: 10.1002/jgh3.12146] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
319 Damião AOMC, Azevedo MFC, Carlos AS, Wada MY, Silva TVM, Feitosa FC. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review. World J Gastroenterol 2019; 25(9): 1142-1157 [PMID: 30863001 DOI: 10.3748/wjg.v25.i9.1142] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 21] [Article Influence: 10.0] [Reference Citation Analysis]
320 Pöllinger B, Schmidt W, Seiffert A, Imhoff H, Emmert M. Costs of dose escalation among ulcerative colitis patients treated with adalimumab in Germany. Eur J Health Econ 2019;20:195-203. [PMID: 29362899 DOI: 10.1007/s10198-017-0953-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
321 Gareb B, Dijkstra G, Kosterink JGW, Frijlink HW. Development of novel zero-order release budesonide tablets for the treatment of ileo-colonic inflammatory bowel disease and comparison with formulations currently used in clinical practice. Int J Pharm 2019;554:366-75. [PMID: 30414898 DOI: 10.1016/j.ijpharm.2018.11.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
322 Vitello A, Grova M, Pugliese D, Rizzello F, Lanzarotto F, Lavagna A, Caccaro R, Cappello M, Viola A, Ribaldone DG, Principi M, Stasi E, Scribano ML, Maida M, Soriano A, Bezzio C, Bodini G, Mocciaro F, Privitera AC, Simondi D, Giuffrida E, D'Incà R, Ricci C, Gionchetti P, Armuzzi A, Orlando A, Daperno M; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy. Dig Liver Dis 2021:S1590-8658(21)00761-1. [PMID: 34538764 DOI: 10.1016/j.dld.2021.08.020] [Reference Citation Analysis]
323 Torres J, Hu J, Seki A, Eisele C, Nair N, Huang R, Tarassishin L, Jharap B, Cote-Daigneault J, Mao Q, Mogno I, Britton GJ, Uzzan M, Chen CL, Kornbluth A, George J, Legnani P, Maser E, Loudon H, Stone J, Dubinsky M, Faith JJ, Clemente JC, Mehandru S, Colombel JF, Peter I. Infants born to mothers with IBD present with altered gut microbiome that transfers abnormalities of the adaptive immune system to germ-free mice. Gut 2020;69:42-51. [PMID: 31036757 DOI: 10.1136/gutjnl-2018-317855] [Cited by in Crossref: 70] [Cited by in F6Publishing: 56] [Article Influence: 35.0] [Reference Citation Analysis]
324 Nielsen OH, Steenholdt C, Juhl CB, Rogler G. Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials. EClinicalMedicine 2020;20:100271. [PMID: 32300735 DOI: 10.1016/j.eclinm.2020.100271] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
325 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos K, Croft N, Navas-López V, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:257-91. [PMID: 30044357 DOI: 10.1097/MPG.0000000000002035] [Cited by in Crossref: 106] [Cited by in F6Publishing: 30] [Article Influence: 35.3] [Reference Citation Analysis]
326 Tang KT, Dufour JF, Chen PH, Hernaez R, Hutfless S. Antitumour necrosis factor-α agents and development of new-onset cirrhosis or non-alcoholic fatty liver disease: a retrospective cohort. BMJ Open Gastroenterol 2020;7:e000349. [PMID: 32377366 DOI: 10.1136/bmjgast-2019-000349] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
327 Mak LY, Tong TSM, Cheung KS, Chen LJ, Lui KL, Lau KS, Leung WK. Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease. Clin Transl Gastroenterol. 2020;11:e00138. [PMID: 32132451 DOI: 10.14309/ctg.0000000000000138] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
328 Mühl L, Becker E, Müller TM, Atreya R, Atreya I, Neurath MF, Zundler S. Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study. BMC Gastroenterol 2021;21:33. [PMID: 33482730 DOI: 10.1186/s12876-021-01604-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
329 Renna S, Mocciaro F, Ventimiglia M, Orlando R, Macaluso FS, Cappello M, Fries W, Mendolaro M, Privitera AC, Ferracane C, Pisana V, Magnano A, Pluchino D, Inserra G, Scarpulla G, Garufi S, Carroccio A, Siringo S, Di Mitri R, Cottone M, Orlando A. A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis. Dig Liver Dis 2018;50:1292-8. [PMID: 30007516 DOI: 10.1016/j.dld.2018.06.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
330 Principi M, Labarile N, Bianchi FP, Contaldo A, Tafuri S, Ierardi E, Di Leo A. The Cost of Inflammatory Bowel Disease Management Matches with Clinical Course: A Single Outpatient Centre Analysis. Int J Environ Res Public Health 2020;17:E4549. [PMID: 32599816 DOI: 10.3390/ijerph17124549] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
331 Chapman TP, Frias Gomes C, Louis E, Colombel J, Satsangi J. Review article: withdrawal of 5-aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 2020;52:73-84. [DOI: 10.1111/apt.15771] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
332 Goldowsky A, Sen R, Hoffman G, Feuerstein JD. Is there a standardized practice for the development of international ulcerative colitis and Crohn's disease treatment guidelines? Gastroenterol Rep (Oxf) 2021;9:408-17. [PMID: 34733526 DOI: 10.1093/gastro/goab009] [Reference Citation Analysis]
333 Triantafyllou C, Nikolaou M, Ikonomidis I, Bamias G, Papaconstantinou I. Endothelial and Cardiac Dysfunction in Inflammatory Bowel Diseases: Does Treatment Modify the Inflammatory Load on Arterial and Cardiac Structure and Function? Curr Vasc Pharmacol 2020;18:27-37. [PMID: 30488796 DOI: 10.2174/1570161117666181129095941] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
334 Brown SR, Fearnhead NS, Faiz OD, Abercrombie JF, Acheson AG, Arnott RG, Clark SK, Clifford S, Davies RJ, Davies MM, Douie WJP, Dunlop MG, Epstein JC, Evans MD, George BD, Guy RJ, Hargest R, Hawthorne AB, Hill J, Hughes GW, Limdi JK, Maxwell-Armstrong CA, O'Connell PR, Pinkney TD, Pipe J, Sagar PM, Singh B, Soop M, Terry H, Torkington J, Verjee A, Walsh CJ, Warusavitarne JH, Williams AB, Williams GL, Wilson RG; ACPGBI IBD Surgery Consensus Collaboration. The Association of Coloproctology of Great Britain and Ireland consensus guidelines in surgery for inflammatory bowel disease. Colorectal Dis. 2018;20 Suppl 8:3-117. [PMID: 30508274 DOI: 10.1111/codi.14448] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
335 Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Vuitton L, Moreau J, Amiot A, Beaugerie L, Ricart E, Dewit O, Lopez-sanroman A, Fumery M, Carbonnel F, Buisson A, Coffin B, Roblin X, van Assche G, Esteve M, Farkkila M, Gisbert JP, Marteau P, Nahon S, de Vos M, Peyrin-biroulet L, Mary J. Evolution of Endoscopic Lesions in Steroid-Refractory Acute Severe Ulcerative Colitis Responding to Infliximab or Cyclosporine. Clinical Gastroenterology and Hepatology 2021;19:1180-1188.e4. [DOI: 10.1016/j.cgh.2020.08.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
336 Sriram A, Tangirala S, Atmakuri S, Hoque S, Modani S, Srivastava S, Mahajan S, Maji I, Kumar R, Khatri D, Madan J, Singh PK. Budding Multi-matrix Technology-a Retrospective Approach, Deep Insights, and Future Perspectives. AAPS PharmSciTech 2021;22:264. [PMID: 34734325 DOI: 10.1208/s12249-021-02133-4] [Reference Citation Analysis]
337 Barberio B, Zamani M, Black CJ, Savarino EV, Ford AC. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2021;6:359-70. [PMID: 33721557 DOI: 10.1016/S2468-1253(21)00014-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
338 Dignass AU, Siegmund B, Goertz R, Schneidewind G, Fanter L. Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis. Scand J Gastroenterol 2019;54:178-87. [PMID: 30735443 DOI: 10.1080/00365521.2019.1569124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
339 Bayoumy AB, Mulder CJJ, Loganayagam A, Sanderson JD, Anderson S, Boekema PJ, Derijks LJJ, Ansari AR. Relationship Between Thiopurine S-Methyltransferase Genotype/Phenotype and 6-Thioguanine Nucleotide Levels in 316 Patients With Inflammatory Bowel Disease on 6-Thioguanine. Ther Drug Monit 2021;43:617-23. [PMID: 34521801 DOI: 10.1097/FTD.0000000000000869] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
340 López-Sanromán A. Steroids and Postoperative Complications in IBD. Curr Drug Targets 2019;20:1323-6. [PMID: 30894107 DOI: 10.2174/1389450120666190320122939] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
341 Hibi T, Kamae I, Pinton P, Ursos L, Iwakiri R, Hather G, Patel H. Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis. Intest Res 2021;19:53-61. [PMID: 32312035 DOI: 10.5217/ir.2019.09146] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
342 Gundersen MD, Goll R, Fenton CG, Anderssen E, Sørbye SW, Florholmen JR, Paulssen RH. Fibrosis Mediators in the Colonic Mucosa of Acute and Healed Ulcerative Colitis. Clin Transl Gastroenterol 2019;10:e00082. [PMID: 31584460 DOI: 10.14309/ctg.0000000000000082] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
343 Cohen-Mekelburg S, Waljee AK. Inflammatory Bowel Disease in the Older Adult. Clin Geriatr Med 2021;37:185-95. [PMID: 33213772 DOI: 10.1016/j.cger.2020.08.013] [Reference Citation Analysis]
344 Damião AOMC, Queiroz NSF. Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough. Clin Colon Rectal Surg 2022;35:032-43. [DOI: 10.1055/s-0041-1740036] [Reference Citation Analysis]
345 Blackwell J, Saxena S, Alexakis C, Bottle A, Cecil E, Majeed A, Pollok RC. The impact of smoking and smoking cessation on disease outcomes in ulcerative colitis: a nationwide population-based study. Aliment Pharmacol Ther. 2019;50:556-567. [PMID: 31389044 DOI: 10.1111/apt.15390] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
346 Bazarganipour S, Hausmann J, Oertel S, El-Hindi K, Brachtendorf S, Blumenstein I, Kubesch A, Sprinzl K, Birod K, Hahnefeld L, Trautmann S, Thomas D, Herrmann E, Geisslinger G, Schiffmann S, Grösch S. The Lipid Status in Patients with Ulcerative Colitis: Sphingolipids are Disease-Dependent Regulated. J Clin Med 2019;8:E971. [PMID: 31277430 DOI: 10.3390/jcm8070971] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
347 Endo K, Satoh T, Yoshino Y, Kondo S, Kawakami Y, Katayama T, Sasaki Y, Takasu A, Kogure T, Hirota M, Meguro T, Satoh K. Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Noninvasive Predictors of the Therapeutic Outcomes of Systemic Corticosteroid Therapy in Ulcerative Colitis. Inflamm Intest Dis 2021;6:218-24. [PMID: 35083287 DOI: 10.1159/000520523] [Reference Citation Analysis]
348 Blackwell J, Selinger C, Raine T, Parkes G, Smith MA, Pollok R. Steroid use and misuse: a key performance indicator in the management of IBD. Frontline Gastroenterol 2021;12:207-13. [PMID: 33907617 DOI: 10.1136/flgastro-2019-101288] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
349 Lee HS, Park SK, Park DI. Novel treatments for inflammatory bowel disease. Korean J Intern Med 2018;33:20-7. [PMID: 29223139 DOI: 10.3904/kjim.2017.393] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
350 Limdi JK, Farraye J, Cannon R, Woodhams E, Farraye FA. Contraception, Venous Thromboembolism, and Inflammatory Bowel Disease: What Clinicians (and Patients) Should Know. Inflamm Bowel Dis. 2019;25:1603-1612. [PMID: 30877770 DOI: 10.1093/ibd/izz025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
351 Yang H, Wu K, Zhang H, Owyang Q, Miao Y, Gu F, Hu N, Zou K, Sheng J, Li J, Zheng P, Liu Y, Li J, Wang X, Wu Y, Yuan Y, Chen C, Pang Y, Cui M, Qian J. IgA, albumin, and eosinopenia as early indicators of cytomegalovirus infection in patients with acute ulcerative colitis. BMC Gastroenterol 2020;20:294. [PMID: 32891125 DOI: 10.1186/s12876-020-01434-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
352 Pabla BS, Schwartz DA. Assessing Severity of Disease in Patients with Ulcerative Colitis. Gastroenterol Clin North Am 2020;49:671-88. [PMID: 33121688 DOI: 10.1016/j.gtc.2020.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
353 Ballester MP, Mesonero F, Flórez-Diez P, Gómez C, Fuentes-Valenzuela E, Martín N, Senosiain C, Vela M, Fernández-Clotet A, Pérez P, Rubín de Célix C, Calviño-Suárez C, Hermida B, Muñoz R, González-Vivo M, Brunet E, Jiménez N, Botella B, Yebra J, Suárez-Ferrer C, Bouhmidi A, López-Serrano A, Ponferrada Á, Dueñas C, Mínguez M; Young Group of AEG and GETECCU. Adherence to endoscopic surveillance for advanced lesions and colorectal cancer in inflammatory bowel disease: an AEG and GETECCU collaborative cohort study. Aliment Pharmacol Ther 2022;55:1402-13. [PMID: 35224758 DOI: 10.1111/apt.16832] [Reference Citation Analysis]
354 Annese V. An update on treatment of ulcerative colitis. Expert Opinion on Orphan Drugs 2019;7:295-304. [DOI: 10.1080/21678707.2019.1638249] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
355 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
356 Nishida A, Nishino K, Sakai K, Owaki Y, Noda Y, Imaeda H. Can control of gut microbiota be a future therapeutic option for inflammatory bowel disease? World J Gastroenterol 2021; 27(23): 3317-3326 [PMID: 34163114 DOI: 10.3748/wjg.v27.i23.3317] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
357 Salas A, Hernandez-Rocha C, Duijvestein M, Faubion W, McGovern D, Vermeire S, Vetrano S, Vande Casteele N. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2020;17:323-37. [PMID: 32203403 DOI: 10.1038/s41575-020-0273-0] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 31.5] [Reference Citation Analysis]
358 Iborra M, Herreras J, Boscá-Watts MM, Cortés X, Trejo G, Cerrillo E, Hervás D, Mínguez M, Beltrán B, Nos P. Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse. Dig Dis Sci 2019;64:1612-21. [PMID: 30604371 DOI: 10.1007/s10620-018-5429-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
359 Goetgebuer RL, Kreijne JE, Aitken CA, Dijkstra G, Hoentjen F, de Boer NK, Oldenburg B, van der Meulen AE, Ponsioen CIJ, Pierik MJ, van Kemenade FJ, de Kok IMCM, Siebers AG, Manniën J, van der Woude CJ, de Vries AC. Increased risk of high-grade cervical neoplasia in women with inflammatory bowel disease: a case-controlled cohort study. J Crohns Colitis 2021:jjab036. [PMID: 33609353 DOI: 10.1093/ecco-jcc/jjab036] [Reference Citation Analysis]
360 D'Amico F, Fiorino G, Furfaro F, Allocca M, Roda G, Loy L, Zilli A, Solitano V, Peyrin-Biroulet L, Danese S. Patient's profiling for therapeutic management of inflammatory bowel disease: a tailored approach. Expert Rev Gastroenterol Hepatol 2020;14:765-73. [PMID: 32427002 DOI: 10.1080/17474124.2020.1772057] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
361 Yamamoto-Furusho JK, Sarmiento-Aguilar A, Toledo-Mauriño JJ, Bozada-Gutiérrez KE, Bosques-Padilla FJ, Martínez-Vázquez MA, Marroquín-Jiménez V, García-Figueroa R, Jaramillo-Buendía C, Miranda-Cordero RM, Valenzuela-Pérez JA, Cortes-Aguilar Y, Jacobo-Karam JS, Bermudez-Villegas EF; EPIMEX Study Group. Incidence and prevalence of inflammatory bowel disease in Mexico from a nationwide cohort study in a period of 15 years (2000-2017). Medicine (Baltimore) 2019;98:e16291. [PMID: 31277162 DOI: 10.1097/MD.0000000000016291] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 6.7] [Reference Citation Analysis]
362 Panés J, Alfaro I. New treatment strategies for ulcerative colitis. Expert Rev Clin Immunol 2017;13:963-73. [PMID: 28617055 DOI: 10.1080/1744666X.2017.1343668] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
363 Dotan I, Allez M, Danese S, Keir M, Tole S, McBride J. The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies. Med Res Rev 2020;40:245-62. [PMID: 31215680 DOI: 10.1002/med.21601] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
364 Hoffmann P, Wehling C, Krisam J, Pfeiffenberger J, Belling N, Gauss A. Performance of tacrolimus in hospitalized patients with steroid-refractory acute severe ulcerative colitis. World J Gastroenterol 2019; 25(13): 1603-1617 [PMID: 30983820 DOI: 10.3748/wjg.v25.i13.1603] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
365 Solitano V, D'Amico F, Correale C, Peyrin-Biroulet L, Danese S. Thiopurines and non-melanoma skin cancer: partners in crime in inflammatory bowel diseases. Br Med Bull 2020;136:107-17. [PMID: 33200781 DOI: 10.1093/bmb/ldaa033] [Reference Citation Analysis]
366 Deissler H, Krammer H, Gillessen A. pH-dependent vs. constant release of mesalazine in the treatment of ulcerative colitis: Do drug delivery concepts determine therapeutic efficacy? (Review). Biomed Rep 2021;15:96. [PMID: 34631051 DOI: 10.3892/br.2021.1472] [Reference Citation Analysis]
367 Privitera G, Pugliese D, Onali S, Petito V, Scaldaferri F, Gasbarrini A, Danese S, Armuzzi A. Combination therapy in inflammatory bowel disease - from traditional immunosuppressors towards the new paradigm of dual targeted therapy. Autoimmun Rev 2021;20:102832. [PMID: 33866066 DOI: 10.1016/j.autrev.2021.102832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
368 Nascimento C, Oliveira H, Fidalgo C, Ramos L, Glória L, Torres J. Aggressive Colorectal Cancer in an Inflammatory Bowel Disease Patient following Treatment with Vedolizumab: A Case Report. GE Port J Gastroenterol. [DOI: 10.1159/000516673] [Reference Citation Analysis]
369 Li PH, Tang Y, Wen HZ. Qingchang decoction retention enema may induce clinical and mucosal remission in left-sided ulcerative colitis: A case report. World J Clin Cases 2022; 10(11): 3573-3578 [DOI: 10.12998/wjcc.v10.i11.3573] [Reference Citation Analysis]
370 Nishida Y, Hosomi S, Watanabe K, Watanabe K, Yukawa T, Otani K, Nagami Y, Tanaka F, Taira K, Kamata N, Yamagami H, Tanigawa T, Watanabe T, Fujiwara Y. Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis. Scand J Gastroenterol 2018;53:579-85. [PMID: 29171305 DOI: 10.1080/00365521.2017.1403647] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
371 D'Amico F, Parigi TL, Bonovas S, Peyrin-Biroulet L, Danese S. Long-term safety of approved biologics for ulcerative colitis. Expert Opin Drug Saf 2020;19:807-16. [PMID: 32441228 DOI: 10.1080/14740338.2020.1773430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
372 Chimenti MS, Conigliaro P, Biancone L, Perricone R. Update on the therapeutic management of patients with either psoriatic arthritis or ulcerative colitis: focus on the JAK inhibitor tofacitinib. Ther Adv Musculoskelet Dis 2021;13:1759720X20977777. [PMID: 33680096 DOI: 10.1177/1759720X20977777] [Reference Citation Analysis]
373 Ribiere S, Leconte M, Chaussade S, Abitbol V. [Acute severe colitis]. Presse Med 2018;47:312-9. [PMID: 29618409 DOI: 10.1016/j.lpm.2018.02.020] [Reference Citation Analysis]
374 Debnath P, Rathi PM. Vedolizumab in Inflammatory Bowel Disease: West versus East. Inflamm Intest Dis 2021;6:1-17. [PMID: 33850834 DOI: 10.1159/000512805] [Reference Citation Analysis]
375 Aluzaite K, Nuttall JW, O'Connor M, Harvie R, Schultz M. Quality of life in postostomy surgery patients: A cross-sectional survey. JGH Open 2020;4:987-94. [PMID: 33102774 DOI: 10.1002/jgh3.12383] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
376 Triantafyllou C, Nikolaou M, Ikonomidis I, Bamias G, Kouretas D, Andreadou I, Tsoumani M, Thymis J, Papaconstantinou I. Effects of Anti-Inflammatory Treatment and Surgical Intervention on Endothelial Glycocalyx, Peripheral and Coronary Microcirculatory Function and Myocardial Deformation in Inflammatory Bowel Disease Patients: A Two-Arms Two-Stage Clinical Trial. Diagnostics (Basel) 2021;11:993. [PMID: 34070768 DOI: 10.3390/diagnostics11060993] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
377 Herfarth H, Barnes EL, Valentine JF, Hanson J, Higgins PDR, Isaacs KL, Jackson S, Osterman MT, Anton K, Ivanova A, Long MD, Martin C, Sandler RS, Abraham B, Cross RK, Dryden G, Fischer M, Harlan W, Levy C, McCabe R, Polyak S, Saha S, Williams E, Yajnik V, Serrano J, Sands BE, Lewis JD; Clinical Research Alliance of the Crohn’s and Colitis Foundation. Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis. Gastroenterology 2018;155:1098-1108.e9. [PMID: 29964043 DOI: 10.1053/j.gastro.2018.06.046] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 8.8] [Reference Citation Analysis]
378 Privitera G, Pugliese D, Lopetuso LR, Scaldaferri F, Neri M, Guidi L, Gasbarrini A, Armuzzi A. Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches. Therap Adv Gastroenterol 2021;14:17562848211006669. [PMID: 33995579 DOI: 10.1177/17562848211006669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
379 Powell N, Ibraheim H, Raine T, Speight RA, Papa S, Brain O, Green M, Samaan MA, Spain L, Yousaf N, Hunter N, Eldridge L, Pavlidis P, Irving P, Hayee B, Turajlic S, Larkin J, Lindsay JO, Gore M. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. Lancet Gastroenterol Hepatol 2020;5:679-97. [PMID: 32553146 DOI: 10.1016/S2468-1253(20)30014-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
380 Zaltman C, Parra RS, Sassaki LY, Santana GO, Ferrari MLA, Miszputen SJ, Amarante HMBS, Kaiser Junior RL, Flores C, Catapani WR, Parente JML, Bafutto M, Ramos O, Gonçalves CD, Guimaraes IM, da Rocha JJR, Feitosa MR, Feres O, Saad-Hossne R, Penna FGC, Cunha PFS, Gomes TN, Nones RB, Faria MAG, Parente MPPD, Scotton AS, Caratin RF, Senra J, Chebli JM. Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil. World J Gastroenterol 2021; 27(2): 208-223 [PMID: 33510560 DOI: 10.3748/wjg.v27.i2.208] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
381 Gareb B, Otten AT, Frijlink HW, Dijkstra G, Kosterink JGW. Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease. Pharmaceutics 2020;12:E539. [PMID: 32545207 DOI: 10.3390/pharmaceutics12060539] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
382 Pagnini C, Di Paolo MC, Graziani MG, Delle Fave G. Probiotics and Vitamin D/Vitamin D Receptor Pathway Interaction: Potential Therapeutic Implications in Inflammatory Bowel Disease. Front Pharmacol 2021;12:747856. [PMID: 34899302 DOI: 10.3389/fphar.2021.747856] [Reference Citation Analysis]
383 Gargallo-Puyuelo CJ, Laredo V, Gomollón F. Thiopurines in Inflammatory Bowel Disease. How to Optimize Thiopurines in the Biologic Era? Front Med (Lausanne) 2021;8:681907. [PMID: 34336887 DOI: 10.3389/fmed.2021.681907] [Reference Citation Analysis]
384 Liefferinckx C, Cremer A, Franchimont D. Switching biologics used in inflammatory bowel diseases: how to deal with in practice? Curr Opin Pharmacol 2020;55:82-9. [PMID: 33166871 DOI: 10.1016/j.coph.2020.10.003] [Reference Citation Analysis]
385 Roda G, Dal Buono A, Argollo M, Danese S. JAK selectivity: more precision less troubles. Expert Rev Gastroenterol Hepatol 2020;14:789-96. [PMID: 32520647 DOI: 10.1080/17474124.2020.1780120] [Reference Citation Analysis]
386 Daperno M, Armuzzi A, Danese S, Fries W, Liguori G, Orlando A, Papi C, Principi M, Rizzello F, Viscido A, Gionchetti P. Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus. Gastroenterol Res Pract 2019;2019:3108025. [PMID: 31565051 DOI: 10.1155/2019/3108025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
387 Mascarenhas Saraiva M, Ribeiro T, Dias E, Lopes JL, Cardoso H, Macedo G. Vedolizumab-Induced Liver Injury. GE Port J Gastroenterol 2021;28:410-5. [PMID: 34901448 DOI: 10.1159/000511644] [Reference Citation Analysis]
388 Pugliese D, Aratari A, Festa S, Ferraro PM, Monterubbianesi R, Guidi L, Scribano ML, Papi C, Armuzzi A. Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study. Gastroenterol Res Pract 2018;2018:4195968. [PMID: 30402090 DOI: 10.1155/2018/4195968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
389 Meredith J, Henderson P, Wilson DC, Russell RK. Combination Immunotherapy Use and Withdrawal in Pediatric Inflammatory Bowel Disease-A Review of the Evidence. Front Pediatr 2021;9:708310. [PMID: 34621712 DOI: 10.3389/fped.2021.708310] [Reference Citation Analysis]
390 Jeong DY, Kim S, Son MJ, Son CY, Kim JY, Kronbichler A, Lee KH, Shin JI. Induction and maintenance treatment of inflammatory bowel disease: A comprehensive review. Autoimmun Rev 2019;18:439-54. [PMID: 30844556 DOI: 10.1016/j.autrev.2019.03.002] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 15.3] [Reference Citation Analysis]
391 Venkataraman B, Ojha S, Belur PD, Bhongade B, Raj V, Collin PD, Adrian TE, Subramanya SB. Phytochemical drug candidates for the modulation of peroxisome proliferator-activated receptor γ in inflammatory bowel diseases. Phytother Res 2020;34:1530-49. [PMID: 32009281 DOI: 10.1002/ptr.6625] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
392 Stevens TW, Matheeuwsen M, Lönnkvist MH, Parker CE, Wildenberg ME, Gecse KB, D’haens GR. Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy. Aliment Pharmacol Ther 2018;48:1213-31. [DOI: 10.1111/apt.15033] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
393 Weislinger L, Guillo L, D'Amico F, Danese S, Achit H, Ayav C, Guillemin F, Peyrin-Biroulet L, Frimat L. Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2021;33:1148-52. [PMID: 33252416 DOI: 10.1097/MEG.0000000000002008] [Reference Citation Analysis]
394 Arjomandnejad M, Kopec AL, Keeler AM. CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications. Biomedicines 2022;10:287. [PMID: 35203496 DOI: 10.3390/biomedicines10020287] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
395 Cassinotti A, Corona A, Duca P, Nebuloni M, Maconi G, Fociani P, Ardizzone S. Noninvasive Monitoring After Azathioprine Withdrawal in Patients With Inflammatory Bowel Disease in Deep Remission. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00642-X. [PMID: 34139332 DOI: 10.1016/j.cgh.2021.06.014] [Reference Citation Analysis]
396 Fossmark R, Olaisen M, Martinsen TC, Melberg HO. Factors associated with the persistence of oral 5-aminosalicylic acid monotherapy in ulcerative colitis: a nationwide Norwegian cohort study. Therap Adv Gastroenterol 2021;14:17562848211021760. [PMID: 34262610 DOI: 10.1177/17562848211021760] [Reference Citation Analysis]
397 Nijakowski K, Rutkowski R, Eder P, Simon M, Korybalska K, Witowski J, Surdacka A. Potential Salivary Markers for Differential Diagnosis of Crohn's Disease and Ulcerative Colitis. Life (Basel) 2021;11:943. [PMID: 34575091 DOI: 10.3390/life11090943] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
398 Danese S, Hart A, Dignass A, Fiorino G, Louis E, Bonovas S, D'Haens G, Dotan I, Rogler G, Paridaens K, Peyrin-Biroulet L. A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®MMX®) for active, mild-to-moderate ulcerative colitis. United European Gastroenterol J 2019;7:1171-82. [PMID: 31700630 DOI: 10.1177/2050640619864848] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
399 Parigi TL, Roda G, Argollo M, Gilardi D, Danese S, Peyrin-biroulet L. Is there a role for therapeutic sphingolipids in inflammatory bowel disease? Expert Review of Gastroenterology & Hepatology 2020;14:47-54. [DOI: 10.1080/17474124.2020.1709446] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
400 Pouillon L, Bossuyt P, Vanderstukken J, Moulin D, Netter P, Danese S, Jouzeau JY, Loeuille D, Peyrin-Biroulet L. Management of patients with inflammatory bowel disease and spondyloarthritis. Expert Rev Clin Pharmacol. 2017;10:1363-1374. [PMID: 28879780 DOI: 10.1080/17512433.2017.1377609] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
401 Ala M. Tryptophan metabolites modulate inflammatory bowel disease and colorectal cancer by affecting immune system. Int Rev Immunol 2021;:1-20. [PMID: 34289794 DOI: 10.1080/08830185.2021.1954638] [Reference Citation Analysis]
402 Hazel K, O'Connor A. Emerging treatments for inflammatory bowel disease. Ther Adv Chronic Dis 2020;11:2040622319899297. [PMID: 32076497 DOI: 10.1177/2040622319899297] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 14.0] [Reference Citation Analysis]
403 Thomas MG, Bayliss C, Bond S, Dowling F, Galea J, Jairath V, Lamb C, Probert C, Timperley-Preece E, Watson A, Whitehead L, Williams JG, Parkes M, Kaser A, Raine T. Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. BMJ Open 2019;9:e023765. [PMID: 30772849 DOI: 10.1136/bmjopen-2018-023765] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
404 O’connell J, Rowan C, Stack R, Harkin G, Parihar V, Chan G, Breslin N, Cullen G, Dunne C, Egan L, Harewood G, Leyden J, Maccarthy F, Macmathuna P, Mahmud N, Mckiernan S, Mcnamara D, Mulcahy H, Murray F, O’connor A, O’toole A, Patchett S, Ryan B, Sheridan J, Slattery E, Doherty G, Kevans D. Golimumab effectiveness and safety in clinical practice for moderately active ulcerative colitis. European Journal of Gastroenterology & Hepatology 2018;30:1019-26. [DOI: 10.1097/meg.0000000000001177] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
405 Dal Buono A, Carvello M, Sachar DB, Spinelli A, Danese S, Roda G. Diversion proctocolitis and the problem of the forgotten rectum in inflammatory bowel diseases: A systematic review. United European Gastroenterol J 2021;9:1157-67. [PMID: 34845854 DOI: 10.1002/ueg2.12175] [Reference Citation Analysis]
406 Radziszewska M, Smarkusz-Zarzecka J, Ostrowska L, Pogodziński D. Nutrition and Supplementation in Ulcerative Colitis. Nutrients 2022;14:2469. [PMID: 35745199 DOI: 10.3390/nu14122469] [Reference Citation Analysis]
407 Iacucci M, Cannatelli R, Labarile N, Mao R, Panaccione R, Danese S, Kochhar GS, Ghosh S, Shen B. Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period. Lancet Gastroenterol Hepatol 2020;5:598-606. [PMID: 32305075 DOI: 10.1016/S2468-1253(20)30119-9] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 21.0] [Reference Citation Analysis]
408 Jentzer A, Veyrard P, Roblin X, Saint-Sardos P, Rochereau N, Paul S, Bourlet T, Pozzetto B, Pillet S. Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC). Microorganisms 2020;8:E1078. [PMID: 32698383 DOI: 10.3390/microorganisms8071078] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
409 Bargo D, Tritton T, Cappelleri JC, DiBonaventura M, Smith TW, Tsuchiya T, Gardiner S, Modesto I, Holbrook T, Bluff D, Kobayashi T. Living with Ulcerative Colitis in Japan: Biologic Persistence and Health-Care Resource Use. Inflamm Intest Dis 2021;6:186-98. [PMID: 35083284 DOI: 10.1159/000519123] [Reference Citation Analysis]
410 Mazza S, Piazza O Sed N, Conforti FS, Fascì A, Rimondi A, Marinoni B, Casini V, Ricci C, Munari F, Pirola L, Invernizzi P, Girelli C, Lupinacci G, Pastorelli L, Cavallaro F, Ferraris L, Colucci A, Amato A, Eugenio Tontini G, Vecchi M, Fiorino G, Caprioli F. Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study. Clin Transl Sci 2021. [PMID: 34523800 DOI: 10.1111/cts.13131] [Reference Citation Analysis]
411 Petryszyn P, Ekk-Cierniakowski P, Zurakowski G. Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland. Therap Adv Gastroenterol 2020;13:1756284820941179. [PMID: 32922513 DOI: 10.1177/1756284820941179] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
412 Shen H, Zhang S, Zhao W, Ren S, Ke X, Gu Q, Tang Z, Xie J, Chen S, Chen Y, Zou J, Zhang L, Shen Z, Zheng K, Liu Y, Gu P, Cheng J, Hu J, Zhu L. Randomised clinical trial: Efficacy and safety of Qing-Chang-Hua-Shi granules in a multicenter, randomized, and double-blind clinical trial of patients with moderately active ulcerative colitis. Biomed Pharmacother 2021;139:111580. [PMID: 33857914 DOI: 10.1016/j.biopha.2021.111580] [Reference Citation Analysis]
413 Barberio B, Black CJ, Savarino EV, Ford AC. Ciclosporin or Infliximab as Rescue Therapy in Acute Glucorticosteroid-Refractory Ulcerative Colitis: Systematic Review and Network Meta-Analysis. J Crohns Colitis 2021;15:733-41. [PMID: 33175102 DOI: 10.1093/ecco-jcc/jjaa226] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
414 Yuan Y, Hu Q, Liu L, Xie F, Yang L, Li Y, Zhang C, Chen H, Tang J, Shen X. Dehydrocostus Lactone Suppresses Dextran Sulfate Sodium-Induced Colitis by Targeting the IKKα/β-NF-κB and Keap1-Nrf2 Signalling Pathways. Front Pharmacol 2022;13:817596. [DOI: 10.3389/fphar.2022.817596] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
415 Duricova D, Pariente B, Sarter H, Fumery M, Leroyer A, Charpentier C, Armengol-Debeir L, Peyrin-Biroulet L, Savoye G, Gower-Rousseau C; Epimad Group. Impact of age at diagnosis on natural history of patients with elderly-onset ulcerative colitis: A French population-based study. Dig Liver Dis 2018;50:903-9. [PMID: 29739650 DOI: 10.1016/j.dld.2018.04.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
416 Michalopoulos G, Karmiris K. When disease extent is not always a key parameter: Management of refractory ulcerative proctitis. Curr Res Pharmacol Drug Discov 2022;3:100071. [PMID: 34988432 DOI: 10.1016/j.crphar.2021.100071] [Reference Citation Analysis]
417 Fischer S, Rath T, Neurath MF. [Inflammatory bowel diseases : Crohn's disease and ulcerative colitis]. Internist (Berl) 2018;59:681-93. [PMID: 29872891 DOI: 10.1007/s00108-018-0442-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
418 Tominaga K, Sugaya T, Tanaka T, Kanazawa M, Iijima M, Irisawa A. Thiopurines: Recent Topics and Their Role in the Treatment of Inflammatory Bowel Diseases. Front Pharmacol 2020;11:582291. [PMID: 33584261 DOI: 10.3389/fphar.2020.582291] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
419 Salice M, Rizzello F, Calabrese C, Privitera Hrustemovic H, Gionchetti P. Budesonide MMX: efficacy and safety profile in the treatment of ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2019;13:607-13. [DOI: 10.1080/17474124.2019.1621745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
420 Rasmussen B, Haastrup P, Wehberg S, Kjeldsen J, Waldorff FB. Predictors of health-related quality of life in patients with moderate to severely active ulcerative colitis receiving biological therapy. Scand J Gastroenterol 2020;55:656-63. [PMID: 32442051 DOI: 10.1080/00365521.2020.1768282] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
421 Lee SD, Shivashankar R, Quirk D, Zhang H, Telliez JB, Andrews J, Marren A, Mukherjee A, Loftus EV Jr. Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments. J Clin Gastroenterol 2021;55:195-206. [PMID: 32740098 DOI: 10.1097/MCG.0000000000001396] [Reference Citation Analysis]
422 Kredel LI, Schneidereit O, Hoffmann JC, Siegmund B, Preiß JC. Guideline recommendations for treatment of patients with inflammatory bowel diseases are not implemented in clinical practice-results of a non-representative survey. Int J Colorectal Dis 2019;34:431-40. [PMID: 30523398 DOI: 10.1007/s00384-018-3215-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
423 Magdziak A, Szlak J, Mróz A, Wieszczy P, Zagórowicz E. A stool test in patients with active ulcerative colitis helps exclude cytomegalovirus disease. Scand J Gastroenterol 2020;55:664-70. [PMID: 32552149 DOI: 10.1080/00365521.2020.1771760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
424 Brookes MJ, Waller J, Cappelleri JC, Modesto I, DiBonaventura MD, Bohm N, Mokgokong R, Massey O, Wood R, Bargo D. Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis. BMJ Open Gastroenterol 2020;7:e000456. [PMID: 32938582 DOI: 10.1136/bmjgast-2020-000456] [Reference Citation Analysis]
425 Chu TPC, Grainge MJ, Card TR. Letter: different risks of venous thromboembolism in subsets of patients with inflammatory bowel diseases - authors' reply. Aliment Pharmacol Ther 2019;49:346. [PMID: 30663105 DOI: 10.1111/apt.15103] [Reference Citation Analysis]
426 Jmour O, Pellat A, Colson-Durand L, To NH, Latorzeff I, Sargos P, Sobhani I, Belkacemi Y. [Radiation therapy in patients with inflammatory bowel disease. A review]. Bull Cancer 2018;105:517-22. [PMID: 29653817 DOI: 10.1016/j.bulcan.2018.02.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
427 Sardesai A, Dignass A, Quon P, Milev S, Cappelleri JC, Kisser A, Modesto I, Sharma PP. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany. J Med Econ 2021;24:279-90. [PMID: 33502905 DOI: 10.1080/13696998.2021.1881323] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
428 Lie MRKL, Kreijne JE, Dijkstra G, Löwenberg M, van Assche G, West RL, van Noord D, van der Meulen-de Jong AE, Oldenburg B, Zaal RJ, Hansen BE, de Vries AC, Janneke van der Woude C; Dutch Initiative on Crohn and Colitis. No Superiority of Tacrolimus Suppositories vs Beclomethasone Suppositories in a Randomized Trial of Patients With Refractory Ulcerative Proctitis. Clin Gastroenterol Hepatol 2020;18:1777-1784.e2. [PMID: 31610337 DOI: 10.1016/j.cgh.2019.09.049] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
429 Paramsothy S, Rosenstein AK, Mehandru S, Colombel JF. The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol 2018;11:1558-70. [PMID: 29907872 DOI: 10.1038/s41385-018-0050-3] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
430 Lim SZ, Chua EW. Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring. Front Pharmacol. 2018;9:1107. [PMID: 30349479 DOI: 10.3389/fphar.2018.01107] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
431 Alhalabi MM, Abbas AJ. Subcutaneous golimumab to treat a biological naïve chronically active ulcerative colitis child. A case report. Annals of Medicine and Surgery 2022;75:103456. [DOI: 10.1016/j.amsu.2022.103456] [Reference Citation Analysis]
432 Kirchgesner J, Lemaitre M, Carrat F, Zureik M, Carbonnel F, Dray-Spira R. Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. Gastroenterology. 2018;155:337-346.e10. [PMID: 29655835 DOI: 10.1053/j.gastro.2018.04.012] [Cited by in Crossref: 194] [Cited by in F6Publishing: 176] [Article Influence: 48.5] [Reference Citation Analysis]
433 Dorrington AM, Selinger CP, Parkes GC, Smith M, Pollok RC, Raine T. The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease. J Crohns Colitis. 2020;14:1316-1329. [PMID: 32170314 DOI: 10.1093/ecco-jcc/jjaa053] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 11.0] [Reference Citation Analysis]
434 Cross RK, Herfarth H. Is There a Role for Thiopurines in IBD? Am J Gastroenterol 2018;113:1121-4. [PMID: 29946181 DOI: 10.1038/s41395-018-0175-8] [Reference Citation Analysis]
435 Chhibba T, Ma C. Is there room for immunomodulators in ulcerative colitis? Expert Opin Biol Ther 2020;20:379-90. [PMID: 31874578 DOI: 10.1080/14712598.2020.1708896] [Reference Citation Analysis]
436 Quaresma AB, Coy CSR, Damião AOMC, Kaplan GG, Kotze PG. BIOLOGICAL THERAPY PENETRATION FOR INFLAMMATORY BOWEL DISEASE IN LATIN AMERICA: CURRENT STATUS AND FUTURE CHALLENGES. Arq Gastroenterol 2019;56:318-22. [DOI: 10.1590/s0004-2803.201900000-59] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
437 Fang S, Song Y, Zhang C, Wang L. Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review. BMC Pediatr 2022;22:175. [PMID: 35379216 DOI: 10.1186/s12887-022-03229-x] [Reference Citation Analysis]
438 Osterman MT, Rosario M, Lasch K, Barocas M, Wilbur JD, Dirks NL, Gastonguay MR. Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation. Aliment Pharmacol Ther 2019;49:408-18. [PMID: 30663076 DOI: 10.1111/apt.15113] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
439 Okabayashi S, Kobayashi T, Saito E, Toyonaga T, Ozaki R, Sagami S, Nakano M, Tanaka J, Yagisawa K, Kuronuma S, Takeuchi O, Hibi T. Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis. Intest Res 2019;17:218-26. [PMID: 30704156 DOI: 10.5217/ir.2018.00117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
440 . Ueg Week 2020 Poster Presentations. United European Gastroenterol j 2020;8:144-887. [DOI: 10.1177/2050640620927345] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
441 Zakerska-banaszak O, Łykowska-szuber L, Walczak M, Żuraszek J, Zielińska A, Skrzypczak-zielińska M. Cytotoxicity of Thiopurine Drugs in Patients with Inflammatory Bowel Disease. Toxics 2022;10:151. [DOI: 10.3390/toxics10040151] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
442 Sahu P, Jain S, Kedia S, Vuyyuru SK, Sahni P, Sharma R, Panwar R, Das P, Gupta V, Makharia G, Travis S, Ahuja V. Prospective validation of AIIMS index as a predictor of steroid failure in patients with acute severe ulcerative colitis. Indian J Gastroenterol 2022. [PMID: 35474175 DOI: 10.1007/s12664-021-01217-0] [Reference Citation Analysis]
443 Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, Veres G, Aloi M, Strisciuglio C, Braegger CP, Assa A, Romano C, Hussey S, Stanton M, Pakarinen M, de Ridder L, Katsanos KH, Croft N, Navas-López VM, Wilson DC, Lawrence S, Russell RK. Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;67:292-310. [PMID: 30044358 DOI: 10.1097/MPG.0000000000002036] [Cited by in Crossref: 64] [Cited by in F6Publishing: 21] [Article Influence: 21.3] [Reference Citation Analysis]
444 Stewart MJ, Bessissow T, Gregor J, Hazel M, In TSH, Karra K, Dajnowiec D, Williamson M, Sattin B. Subcutaneously Administered Anti-TNFs for the Treatment of Ulcerative Colitis: A Retrospective, Propensity Score-Matched, US Health Claims Analysis. Adv Ther 2021;38:4115-29. [PMID: 34159558 DOI: 10.1007/s12325-021-01818-3] [Reference Citation Analysis]
445 Guillo L, D'Amico F, Achit H, Ayav C, Guillemin F, Danese S, Frimat L, Peyrin-Biroulet L. Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know. Dig Liver Dis 2021;53:691-6. [PMID: 33563584 DOI: 10.1016/j.dld.2021.01.015] [Reference Citation Analysis]
446 Bossa F, Biscaglia G, Valvano MR, Costantino G, Lauria A, Clemente R, Ferracane C, Shahini E, Mendolaro M, Grossi L, Mazzuoli S, Rispo A, Pranzo G, Sebkova L, Tursi A, Miranda A, Patturelli M, Spagnuolo R, Ricciardelli C, Sgarro C, Paese P, Inserra G, Azzarone A, Nardone O, Fries W, Buccianti N, Privitera AC, Principi MB, Cappello M, Guglielmi FW, Romano M, Riegler G, Fanigliulo L, Melina R, Andriulli A. Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis. Dig Dis Sci 2020;65:1767-76. [PMID: 31722059 DOI: 10.1007/s10620-019-05904-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
447 Reinglas J, Gonczi L, Verdon C, Bessissow T, Afif W, Wild G, Seidman E, Bitton A, Lakatos PL. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center. Dig Dis Sci 2020;65:2046-53. [PMID: 31813132 DOI: 10.1007/s10620-019-05982-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
448 Negreanu L, Voiosu T, State M, Voiosu A, Bengus A, Mateescu BR. Endoscopy in inflammatory bowel disease: from guidelines to real life. Therap Adv Gastroenterol. 2019;12:1756284819865153. [PMID: 31384307 DOI: 10.1177/1756284819865153] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
449 Baehler C, Brüngger B, Blozik E, Vavricka SR, Schoepfer AM. Real-World Data on Topical Therapies and Annual Health Resource Utilization in Hospitalized Swiss Patients with Ulcerative Colitis. Inflamm Intest Dis 2019;4:144-53. [PMID: 31768387 DOI: 10.1159/000502205] [Reference Citation Analysis]
450 Privitera G, Pugliese D, Rapaccini GL, Gasbarrini A, Armuzzi A, Guidi L. Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases. J Clin Med 2021;10:853. [PMID: 33669579 DOI: 10.3390/jcm10040853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
451 Duan L, Cheng S, Li L, Liu Y, Wang D, Liu G. Natural Anti-Inflammatory Compounds as Drug Candidates for Inflammatory Bowel Disease. Front Pharmacol 2021;12:684486. [PMID: 34335253 DOI: 10.3389/fphar.2021.684486] [Reference Citation Analysis]
452 Higashiyama M, Sugita A, Koganei K, Wanatabe K, Yokoyama Y, Uchino M, Nagahori M, Naganuma M, Bamba S, Kato S, Takeuchi K, Omori T, Takagi T, Matsumoto S, Nagasaka M, Sagami S, Kitamura K, Katsurada T, Sugimoto K, Takatsu N, Saruta M, Sakurai T, Watanabe K, Nakamura S, Suzuki Y, Hokari R. Management of elderly ulcerative colitis in Japan. J Gastroenterol 2019;54:571-86. [PMID: 31025187 DOI: 10.1007/s00535-019-01580-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
453 Altunisi A Jr, Mosli M, Banweer M, Qari Y, Arif FO, Saadah OI. Patterns of Complementary and Alternative Medicine Use in Saudi Arabian Patients With Inflammatory Bowel Disease: A Cross-Sectional Study. Cureus 2020;12:e9687. [PMID: 32944426 DOI: 10.7759/cureus.9687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
454 Miranda-Bautista J, Diéguez L, Rodríguez-Rosales G, Marín-Jiménez I, Menchén L. Cases report: severe colonic bleeding in ulcerative colitis is refractory to selective transcatheter arterial embolization. BMC Gastroenterol 2019;19:55. [PMID: 30991964 DOI: 10.1186/s12876-019-0970-8] [Reference Citation Analysis]
455 De Cristofaro E, Salvatori S, Marafini I, Zorzi F, Alfieri N, Musumeci M, Biancone L, Calabrese E, Monteleone G. Long-Term Outcomes and Predictive Factors of Hospitalized Patients with Severe Ulcerative Colitis Treated with Intravenous Corticosteroids. J Clin Med 2021;10:5413. [PMID: 34830694 DOI: 10.3390/jcm10225413] [Reference Citation Analysis]
456 Bodini G, Demarzo MG, Casagrande E, De Maria C, Kayali S, Ziola S, Giannini EG. Concerns related to COVID-19 pandemic among patients with inflammatory bowel disease and its influence on patient management. Eur J Clin Invest 2020;50:e13233. [PMID: 32294238 DOI: 10.1111/eci.13233] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
457 Lamb CA, O'Byrne S, Keir ME, Butcher EC. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease. J Crohns Colitis 2018;12:S653-68. [PMID: 29767705 DOI: 10.1093/ecco-jcc/jjy060] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
458 Hibi T, Naganuma M, Oda E, Yamada Y, Chujoh Y, Yoshihara R, Watanabe M. Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials. Intest Res 2020;18:56-68. [PMID: 31813214 DOI: 10.5217/ir.2019.00064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
459 Danese S, Banerjee R, Cummings JF, Dotan I, Kotze PG, Leong RWL, Paridaens K, Peyrin-Biroulet L, Scott G, Assche GV, Wehkamp J, Yamamoto-Furusho JK. Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy-Access to Rapid Treatment (iSTART) approach. Intest Res 2018;16:522-8. [PMID: 30321913 DOI: 10.5217/ir.2018.00073] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
460 Adler SN, González Lama Y, Matallana Royo V, Suárez Ferrer C, Schwartz A, Bar-Gil Shitrit A. Comparison of small-bowel colon capsule endoscopy system to conventional colonoscopy for the evaluation of ulcerative colitis activity. Endosc Int Open 2019;7:E1253-61. [PMID: 31579707 DOI: 10.1055/a-0982-2786] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
461 Dignass AU, Paridaens K, Al Awadhi S, Begun J, Cheon JH, Fullarton JR, Louis E, Magro F, Marquez JR, Moschen AR, Narula N, Rydzewska G, Travis SPL. Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis. Scand J Gastroenterol 2021;:1-8. [PMID: 34932423 DOI: 10.1080/00365521.2021.2015801] [Reference Citation Analysis]
462 Allner C, Melde M, Becker E, Fuchs F, Mühl L, Klenske E, Müller L, Morgenstern N, Fietkau K, Hirschmann S, Atreya R, Atreya I, Neurath MF, Zundler S. Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study. BMC Gastroenterol 2020;20:103. [PMID: 32293299 DOI: 10.1186/s12876-020-01253-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
463 Verburgt CM, Heutink WP, Kuilboer LIM, Dickmann JD, van Etten-Jamaludin FS, Benninga MA, de Jonge WJ, Van Limbergen JE, Tabbers MM. Antibiotics in pediatric inflammatory bowel diseases: a systematic review. Expert Rev Gastroenterol Hepatol 2021;15:891-908. [PMID: 34148466 DOI: 10.1080/17474124.2021.1940956] [Reference Citation Analysis]
464 Danese S, Levesque BG, Feagan BG, Jucov A, Bhandari BR, Pai RK, Taylor Meadows K, Kirby BJ, Bruey JM, Olson A, Osterhout R, Van Biene C, Ford J, Aranda R, Raghupathi K, Sandborn WJ. Randomised clinical trial: a phase 1b study of GB004, an oral HIF-1α stabiliser, for treatment of ulcerative colitis. Aliment Pharmacol Ther 2022. [PMID: 35014040 DOI: 10.1111/apt.16753] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
465 Peyrin-biroulet L, Siegmund B, Danese S, Hart A, Magro F, van der Woude J, Armuzzi A; ECCO Governing Board. Letter to the Editor. Journal of Crohn's and Colitis 2022. [DOI: 10.1093/ecco-jcc/jjab225] [Reference Citation Analysis]
466 Mader O, Juillerat P, Biedermann L, Michetti P, Hruz P, Pittet V, Rogler G, Zahnd-Straumann N, Seibold F. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements. United European Gastroenterol J 2021;9:398-406. [PMID: 33203339 DOI: 10.1177/2050640620965106] [Reference Citation Analysis]
467 Banerjee R, Pal P, Hutfless S, Ganesh BG, Reddy DN. Familial aggregation of inflammatory bowel disease in India: prevalence, risks and impact on disease behavior. Intest Res 2019;17:486-95. [PMID: 31370386 DOI: 10.5217/ir.2018.00174] [Cited by in Crossref: 8] [Article Influence: 2.7] [Reference Citation Analysis]
468 Stefancu A, Moisoiu V, Couti R, Andras I, Rahota R, Crisan D, Pavel IE, Socaciu C, Leopold N, Crisan N. Combining SERS analysis of serum with PSA levels for improving the detection of prostate cancer. Nanomedicine 2018;13:2455-67. [DOI: 10.2217/nnm-2018-0127] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
469 Gordon M, Sinopoulou V, Akobeng AK, Pana M, Gasiea R, Moran GW. Tacrolimus (FK506) for induction of remission in corticosteroid-refractory ulcerative colitis. Cochrane Database Syst Rev 2022;4:CD007216. [PMID: 35388476 DOI: 10.1002/14651858.CD007216.pub2] [Reference Citation Analysis]
470 Sabino J, Verstockt B, Vermeire S, Ferrante M. New biologics and small molecules in inflammatory bowel disease: an update. Therap Adv Gastroenterol 2019;12:1756284819853208. [PMID: 31205488 DOI: 10.1177/1756284819853208] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 12.3] [Reference Citation Analysis]
471 Goldstone RN, Steinhagen RM. Abdominal Emergencies in Inflammatory Bowel Disease.Surg Clin North Am. 2019;99:1141-1150. [PMID: 31676053 DOI: 10.1016/j.suc.2019.08.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
472 Armuzzi A, Ardizzone S, Biancone L, Castiglione F, Danese S, Gionchetti P, Orlando A, Rizzello F, Scribano ML, Vecchi M, Daperno M. Ustekinumab in the management of Crohn’s disease: Expert opinion. Digestive and Liver Disease 2018;50:653-60. [DOI: 10.1016/j.dld.2018.02.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
473 Skrzypczak-Zielinska M, Gabryel M, Marszalek D, Dobrowolska A, Slomski R. NGS study of glucocorticoid response genes in inflammatory bowel disease patients. Arch Med Sci 2021;17:417-33. [PMID: 33747278 DOI: 10.5114/aoms.2019.84470] [Reference Citation Analysis]
474 van Linschoten RCA, van Leeuwen N, Nieboer D, Birnie E, Scherpenzeel M, Verweij KE, de Jonge V, Hazelzet JA, van der Woude CJ, West RL, van Noord D; Southwest Netherlands IBD Study Group. Value-based care pathway for inflammatory bowel disease: a protocol for the multicentre longitudinal non-randomised parallel cluster IBD Value study with baseline period. BMJ Open 2022;12:e050539. [PMID: 35022169 DOI: 10.1136/bmjopen-2021-050539] [Reference Citation Analysis]
475 Gordon M, Grafton-clarke C, Sinopoulou V, Akobeng AK; Cochrane Gut Group. Antibiotics for the induction and maintenance of remission in ulcerative colitis. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd013743] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
476 Blackwell J, Alexakis C, Saxena S, Creese H, Bottle A, Petersen I, Hotopf M, Pollok RCG. Association between antidepressant medication use and steroid dependency in patients with ulcerative colitis: a population-based study. BMJ Open Gastroenterol 2021;8:e000588. [PMID: 34045238 DOI: 10.1136/bmjgast-2020-000588] [Reference Citation Analysis]
477 Weisshof R, Ollech JE, El Jurdi K, Yvellez OV, Cohen RD, Sakuraba A, Dalal S, Pekow J, Rubin DT. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis 2019;13:1105-10. [PMID: 30726894 DOI: 10.1093/ecco-jcc/jjz032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
478 Wilke T, Groth A, Long GH, Tatro AR, Sun D. Rate of Adverse Events and Associated Health Care Costs for the Management of Inflammatory Bowel Disease in Germany. Clin Ther 2020;42:130-143.e3. [PMID: 31883702 DOI: 10.1016/j.clinthera.2019.11.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
479 Dignass A, Waller J, Cappelleri JC, Modesto I, Kisser A, Dietz L, DiBonaventura M, Wood R, May M, Libutzki B, Bargo D. Living with ulcerative colitis in Germany: a retrospective analysis of dose escalation, concomitant treatment use and healthcare costs. J Med Econ 2020;23:415-27. [PMID: 31858853 DOI: 10.1080/13696998.2019.1707210] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
480 Ilias A, Gonczi L, Kurti Z, Lakatos PL. Biosimilars in ulcerative colitis: When and for who? Best Practice & Research Clinical Gastroenterology 2018;32-33:35-42. [DOI: 10.1016/j.bpg.2018.05.003] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
481 Luangsirithanya P, Treewaree S, Pongpaibul A, Pausawasdi N, Limsrivilai J. Cytomegalovirus enterocolitis with subsequent diagnosis of coexisting new-onset inflammatory bowel disease: Two case reports and review of the literature. Medicine (Baltimore) 2021;100:e24914. [PMID: 33663126 DOI: 10.1097/MD.0000000000024914] [Reference Citation Analysis]
482 Schreiner P, Yilmaz B, Rossel JB, Franc Y, Misselwitz B, Scharl M, Zeitz J, Frei P, Greuter T, Vavricka SR, Pittet V, Siebenhüner A, Juillerat P, von Känel R, Macpherson AJ, Rogler G, Biedermann L; Swiss IBD Cohort Study Group. Vegetarian or gluten-free diets in patients with inflammatory bowel disease are associated with lower psychological well-being and a different gut microbiota, but no beneficial effects on the course of the disease. United European Gastroenterol J 2019;7:767-81. [PMID: 31316781 DOI: 10.1177/2050640619841249] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
483 Hashash JG, Fadel CGA, Rimmani HH, Sharara AI. Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn's disease and ulcerative colitis. Ann Gastroenterol 2021;34:612-24. [PMID: 34475731 DOI: 10.20524/aog.2021.0645] [Reference Citation Analysis]
484 Wagatsuma K, Yokoyama Y, Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life (Basel) 2021;11:1375. [PMID: 34947906 DOI: 10.3390/life11121375] [Reference Citation Analysis]
485 Kim H, Alten R, Avedano L, Dignass A, Gomollón F, Greveson K, Halfvarson J, Irving PM, Jahnsen J, Lakatos PL, Lee J, Makri S, Parker B, Peyrin-Biroulet L, Schreiber S, Simoens S, Westhovens R, Danese S, Jeong JH. The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs 2020;80:99-113. [PMID: 32002851 DOI: 10.1007/s40265-020-01256-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
486 Ollech JE, Normatov I, Peleg N, Dalal SR, Pekow J, Micic D, Cohen RD, Rubin DT, Sakuraba A. Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis. Int J Colorectal Dis 2020;35:2113-6. [PMID: 32710391 DOI: 10.1007/s00384-020-03703-x] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
487 D'Amico F, Peyrin-Biroulet L, Danese S. Tofacitinib for Acute Severe Colitis: When the going Gets Tough, the Tough Get Going. J Crohns Colitis 2020;14:883-5. [PMID: 32579173 DOI: 10.1093/ecco-jcc/jjaa028] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
488 Higashiyama M, Komoto S, Suzuki Y, Watanabe M, Hibi T, Miura S, Hokari R. Relation of geriatric nutritional risk index with clinical risks in elderly-onset ulcerative colitis. J Gastroenterol Hepatol 2021;36:163-70. [PMID: 32583472 DOI: 10.1111/jgh.15161] [Reference Citation Analysis]
489 D'Amico F, Baumann C, Rousseau H, Danese S, Peyrin-Biroulet L. Phase I, II and III Trials in Inflammatory Bowel Diseases: A Practical Guide for the Non-specialist. J Crohns Colitis 2020;14:710-8. [PMID: 31901097 DOI: 10.1093/ecco-jcc/jjz214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
490 Bernardo S, Fernandes SR, Gonçalves AR, Valente A, Baldaia C, Santos PM, Correia LA. Predicting the Course of Disease in Hospitalized Patients With Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:541-6. [PMID: 30085135 DOI: 10.1093/ibd/izy256] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
491 Fernández-clotet A, Castro-poceiro J, Panés J. JAK Inhibition: The Most Promising Agents in the IBD Pipeline? CPD 2019;25:32-40. [DOI: 10.2174/1381612825666190405141410] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
492 Zhu R, Tang J, Xing C, Nan Q, Liang G, Luo J, Zhou J, Miao Y, Cao Y, Dai S, Lan D. The Distinguishing Bacterial Features From Active and Remission Stages of Ulcerative Colitis Revealed by Paired Fecal Metagenomes. Front Microbiol 2022;13:883495. [DOI: 10.3389/fmicb.2022.883495] [Reference Citation Analysis]
493 Gecse KB, Buskens CJ. Implication of Medical Treatment for Surgical Strategies in IBD. Curr Drug Targets 2019;20:1363-8. [PMID: 31113342 DOI: 10.2174/1389450120666190515095520] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
494 Lam WC, Zhao C, Ma WJ, Yao L. The Clinical and Steroid-Free Remission of Fecal Microbiota Transplantation to Patients with Ulcerative Colitis: A Meta-Analysis. Gastroenterol Res Pract 2019;2019:1287493. [PMID: 31178906 DOI: 10.1155/2019/1287493] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
495 Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Danese S, Rogers R, Bornstein JD, Chen J, Schreiber S, Sands BE, Lirio RA. Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY). Gastroenterology 2021:S0016-5085(21)03126-7. [PMID: 34144047 DOI: 10.1053/j.gastro.2021.06.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
496 Li J, Liu Z, Hu P, Wen Z, Cao Q, Zou X, Chen Y, Wang Y, Zhong J, Shen X, Demuth D, Fadeeva O, Xie L, Chen J, Qian J. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study. BMC Gastroenterol 2022;22:44. [PMID: 35120446 DOI: 10.1186/s12876-021-02074-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
497 González-Lama Y, Sanz J, Bastida G, Campos J, Ferreiro R, Joven B, Gutiérrez A, Juanola X, Sicilia B, Veroz R, P Gisbert J, Chaparro M, Domènech E, Esteve M, Gomollón F. Recommendations by the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the treatment of patients with inflammatory bowel disease associated with spondyloarthritis. Gastroenterol Hepatol 2020;43:273-83. [PMID: 32247533 DOI: 10.1016/j.gastrohep.2020.01.005] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
498 Le Berre C, Roda G, Nedeljkovic Protic M, Danese S, Peyrin-biroulet L. Modern use of 5-aminosalicylic acid compounds for ulcerative colitis. Expert Opinion on Biological Therapy 2020;20:363-78. [DOI: 10.1080/14712598.2019.1666101] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
499 He Q. Cardiocerebral and peripheral vascular risks in inflammatory bowel disease. Shijie Huaren Xiaohua Zazhi 2019; 27(5): 341-346 [DOI: 10.11569/wcjd.v27.i5.341] [Reference Citation Analysis]
500 Lee YI, Park Y, Park SJ, Kim TI, Kim WH, Cheon JH. Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis. Gut Liver 2021;15:232-42. [PMID: 32616683 DOI: 10.5009/gnl19433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
501 Bezzio C, Saibeni S. Severe Inflammatory Bowel Disease Flares and COVID-19: Expand the Gastroenterology-Surgery Team to Include an Infectious Disease Specialist. Gastroenterology 2021;160:2625-6. [PMID: 32553764 DOI: 10.1053/j.gastro.2020.05.082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
502 Salameh R, Kirchgesner J, Allez M, Carbonnel F, Meyer A, Gornet JM, Beaugerie L, Amiot A. Long-term outcome of patients with acute severe ulcerative colitis responding to intravenous steroids. Aliment Pharmacol Ther 2020;51:1096-104. [PMID: 32342994 DOI: 10.1111/apt.15751] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
503 Vuyyuru SK, Kedia S, Kalaivani M, Sahu P, Kante B, Kumar P, Ranjan MK, Makharia G, Ananthakrishnan A, Ahuja V. Efficacy and safety of fecal transplantation versus targeted therapies in ulcerative colitis: network meta-analysis. Future Microbiol 2021;16:1215-27. [PMID: 34590904 DOI: 10.2217/fmb-2020-0242] [Reference Citation Analysis]
504 Reinhold I, Blümel S, Schreiner J, Boyman O, Bögeholz J, Cheetham M, Rogler G, Biedermann L, Scharl M. Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients. Inflamm Intest Dis 2021;6:38-47. [PMID: 33850838 DOI: 10.1159/000511296] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
505 D'Haens GRAM, Lindsay JO, Panaccione R, Schreiber S. Ulcerative Colitis: Shifting Sands. Drugs R D 2019;19:227-34. [PMID: 30827006 DOI: 10.1007/s40268-019-0263-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
506 Attauabi M, Höglund C, Fassov J, Pedersen KB, Hansen HB, Wildt S, Jensen MD, Neumann A, Lind C, Jacobsen HA, Popa AM, Kjeldsen J, Pedersen N, Molazahi A, Haderslev K, Aalykke C, Knudsen T, Cebula W, Munkholm P, Bendtsen F, Seidelin JB, Burisch J. Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. Scand J Gastroenterol 2021;56:1040-8. [PMID: 34224299 DOI: 10.1080/00365521.2021.1946588] [Reference Citation Analysis]
507 Amiot A, Bouguen G, Bonnaud G, Bouhnik Y, Hagege H, Peyrin-Biroulet L; French National Consensus Clinical guidelines for the management of IBD study group. Clinical guidelines for the management of inflammatory bowel disease: Update of a French national consensus. Dig Liver Dis 2021;53:35-43. [PMID: 33160886 DOI: 10.1016/j.dld.2020.10.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
508 Grosen A, Bungum M, Christensen LA, Cordelli E, Larsen OH, Leter G, Julsgaard M, Vestergaard T, Villani P, Hvas CL, Kelsen J. Semen Quality and Sperm DNA Integrity in Patients With Severe Active Inflammatory Bowel Disease and Effects of Tumour Necrosis Factor-alpha Inhibitors. Journal of Crohn's and Colitis 2019;13:564-71. [DOI: 10.1093/ecco-jcc/jjy198] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
509 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
510 Sandborn WJ, Lawendy N, Danese S, Su C, Loftus EV Jr, Hart A, Dotan I, Damião AOMC, Judd DT, Guo X, Modesto I, Wang W, Panés J. Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open-label, long-term extension study with up to 7.0 years of treatment. Aliment Pharmacol Ther 2021. [PMID: 34854095 DOI: 10.1111/apt.16712] [Reference Citation Analysis]
511 Koskensalo V, Aronen P, Färkkilä M, Kylänpää L, Lindström O, Rainio M, Udd M, Jokelainen K, Tenca A. Use of thiopurines is not a risk factor for post-ERC pancreatitis in patients with primary sclerosing cholangitis. Dig Liver Dis 2021;53:1020-7. [PMID: 34116970 DOI: 10.1016/j.dld.2021.05.009] [Reference Citation Analysis]
512 Guo K, Ren J, Gu G, Wang G, Gong W, Wu X, Ren H, Hong Z, Li J. Hesperidin Protects Against Intestinal Inflammation by Restoring Intestinal Barrier Function and Up-Regulating Treg Cells. Mol Nutr Food Res. 2019;63:e1800975. [PMID: 30817082 DOI: 10.1002/mnfr.201800975] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
513 Yoon H, Jangi S, Dulai PS, Boland BS, Prokop LJ, Jairath V, Feagan BG, Sandborn WJ, Singh S. Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients With Ulcerative Colitis: A Systematic Review and Meta-Analysis. Gastroenterology 2020;159:1262-1275.e7. [PMID: 32585306 DOI: 10.1053/j.gastro.2020.06.043] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
514 Hu Y, Ye Z, Wu M, She Y, Li L, Xu Y, Qin K, Hu Z, Yang M, Lu F, Ye Q. The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies. Front Med (Lausanne) 2021;8:766126. [PMID: 34966755 DOI: 10.3389/fmed.2021.766126] [Reference Citation Analysis]
515 Cha N, Oshima N, Kishimoto K, Kotani S, Okimoto E, Yazaki T, Sonoyama H, Oka A, Mishima Y, Shibagaki K, Tobita H, Kawashima K, Ishimura N, Ishihara S. Long-lasting renal dysfunction following tacrolimus induction therapy in ulcerative colitis patients. J Clin Biochem Nutr . [DOI: 10.3164/jcbn.21-139] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
516 Parigi TL, D'Amico F, Peyrin-Biroulet L, Danese S. Evolution of infliximab biosimilar in inflammatory bowel disease: from intravenous to subcutaneous CT-P13. Expert Opin Biol Ther 2021;21:37-46. [PMID: 32799561 DOI: 10.1080/14712598.2020.1811849] [Reference Citation Analysis]
517 Oh GM, Moon W, Seo KI, Jung K, Kim JH, Kim SE, Park MI, Park SJ. Therapeutic Potential of Escherichia coli Nissle 1917 in Clinically Remission-attained Ulcerative Colitis Patients: A Hospital-based Cohort Study. Korean J Gastroenterol 2021;77:12-21. [PMID: 33361702 DOI: 10.4166/kjg.2020.0119] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
518 Dubois E, Moens A, Geelen R, Sabino J, Ferrante M, Vermeire S. Long-term outcomes of patients with ulcerative proctitis: Analysis from a large referral centre cohort. United European Gastroenterol J 2020;8:933-41. [PMID: 32631177 DOI: 10.1177/2050640620941345] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
519 Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2019;17:420-33. [PMID: 31352659 DOI: 10.1007/s11938-019-00244-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
520 Fiorino G, Allocca M, Chaparro M, Coenen S, Fidalgo C, Younge L, Gisbert JP. 'Quality of Care' Standards in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2019;13:127-137. [PMID: 30423033 DOI: 10.1093/ecco-jcc/jjy140] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
521 Sigurdsson GV, Schmidt S, Mellström D, Ohlsson C, Kindblom JM, Lorentzon M, Saalman R. Bone Mass Development from Childhood into Young Adulthood in Patients with Childhood-onset Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2017;23:2215-26. [DOI: 10.1097/mib.0000000000001277] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
522 Eder P, Zielińska A, Karczewski J, Dobrowolska A, Słomski R, Souto EB. How could nanobiotechnology improve treatment outcomes of anti-TNF-α therapy in inflammatory bowel disease? Current knowledge, future directions. J Nanobiotechnology 2021;19:346. [PMID: 34715852 DOI: 10.1186/s12951-021-01090-1] [Reference Citation Analysis]
523 Kochan K, Keskin EB, Seven G, Bas S, Kiremitci S, Gecer M, Senturk H. Effects of tissue cytomegalovirus quantitative polymerase chain reaction in the management of ulcerative colitis flare-ups: Should we wave aside? Arab J Gastroenterol 2021;22:297-304. [PMID: 34872846 DOI: 10.1016/j.ajg.2021.11.005] [Reference Citation Analysis]
524 Nishimura R, Shirasaki T, Tsuchiya K, Miyake Y, Watanabe Y, Hibiya S, Watanabe S, Nakamura T, Watanabe M. Establishment of a system to evaluate the therapeutic effect and the dynamics of an investigational drug on ulcerative colitis using human colonic organoids. J Gastroenterol. 2019;54:608-620. [PMID: 30599053 DOI: 10.1007/s00535-018-01540-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
525 Chan W, Kariyawasam VC, Kim S, Pudipeddi AV, Paramsothy S, Shim HH, Mourad FH, Ding N, Ferrante M, Leong RW. Gastroenterologists’ preference and risk perception on the use of immunomodulators and biological therapies in elderly patients with ulcerative colitis: an international survey. European Journal of Gastroenterology & Hepatology 2020;32:976-83. [DOI: 10.1097/meg.0000000000001768] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
526 Keil R, Wasserbauer M, Zádorová Z, Kojecký V, Hlava Š, Št'ovíček J, Chudý J, Roznětinská M, Drábek J, Kubišová N, Lochmannová J. Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study. Scand J Gastroenterol 2018;53:459-65. [PMID: 29560753 DOI: 10.1080/00365521.2018.1451915] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
527 Guillo L, Delanaye P, Flamant M, Figueres L, Karam S, Lemoine S, Benezech A, Pelletier AL, Amiot A, Caron B, Stefanescu C, Boschetti G, Bouguen G, Rahier JF, Gornet JM, Hugot JP, Bonnet J, Vuitton L, Nachury M, Vidon M, Uzzan M, Serrero M, Dib N, Seksik P, Hebuterne X, Bertocchio JP, Mariat C, Peyrin-Biroulet L. Kidney function monitoring in inflammatory bowel disease: The MONITORED consensus. Dig Liver Dis 2021:S1590-8658(21)00848-3. [PMID: 34866011 DOI: 10.1016/j.dld.2021.11.008] [Reference Citation Analysis]
528 Kruis W, Nguyen P, Morgenstern J, Ramlow W, Dignaß A, Stallmach A, Drebber U. Novel Leucocyte/Thrombocyte Apheresis for Induction of Steroid-Free Remission in Ulcerative Colitis: A Controlled Randomized Pilot Study. J Crohns Colitis 2019;13:949-53. [PMID: 30863856 DOI: 10.1093/ecco-jcc/jjz005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
529 Nishida Y, Hosomi S, Yamagami H, Sugita N, Itani S, Yukawa T, Otani K, Nagami Y, Tanaka F, Taira K, Kamata N, Tanigawa T, Watanabe T, Fujiwara Y. Pretreatment neutrophil-to-lymphocyte ratio predicts clinical relapse of ulcerative colitis after tacrolimus induction. PLoS One. 2019;14:e0213505. [PMID: 30845259 DOI: 10.1371/journal.pone.0213505] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
530 Caron B, Sandborn WJ, Schreiber S, Panaccione R, Danese S, Peyrin-Biroulet L. Drug development for ulcerative proctitis: current concepts. Gut 2021;70:1203-9. [PMID: 33789968 DOI: 10.1136/gutjnl-2021-324108] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
531 Sanders DJ, Inniss S, Sebepos-Rogers G, Rahman FZ, Smith AM. The role of the microbiome in gastrointestinal inflammation. Biosci Rep 2021;41:BSR20203850. [PMID: 34076695 DOI: 10.1042/BSR20203850] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
532 Mezzina N, Campbell Davies SE, Ardizzone S. Nonbiological therapeutic management of ulcerative colitis. Expert Opinion on Pharmacotherapy 2018;19:1747-57. [DOI: 10.1080/14656566.2018.1525361] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
533 Zhang XF, Li P, Ding XL, Chen H, Wang SJ, Jin SB, Guo J, Tian ZB. Comparing the clinical application values of the Degree of Ulcerative Colitis Burden of Luminal Inflammation (DUBLIN) score and Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in patients with ulcerative colitis. Gastroenterol Rep (Oxf) 2021;9:533-42. [PMID: 34925850 DOI: 10.1093/gastro/goab026] [Reference Citation Analysis]
534 Chavoushi SF, Jharap B, Friedrich P, Smid K, Peters GJ, Malingré M. Thiopurines with low-dose allopurinol (ThiLDA)-a prospective clinical one-way crossover trial. Eur J Clin Pharmacol 2019;75:1669-74. [PMID: 31587102 DOI: 10.1007/s00228-019-02760-8] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
535 Ribaldone DG, Adriani A, Caviglia GP, Nicolò A, Agnesod D, Simiele M, Riganò D, Pellicano R, Canaparo R, Perri GD, D'Avolio A, Luzza F, Saracco GM, Astegiano M. Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients. Medicina (Kaunas) 2019;55:E441. [PMID: 31387318 DOI: 10.3390/medicina55080441] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
536 Allocca M, Dell'Avalle C, Craviotto V, Furfaro F, Zilli A, D'Amico F, Bonovas S, Peyrin-Biroulet L, Fiorino G, Danese S. Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study. United European Gastroenterol J 2022. [PMID: 35233934 DOI: 10.1002/ueg2.12206] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
537 Haifer C. Catastrophe prevention: Acute severe ulcerative colitis. J Gastroenterol Hepatol 2021;36 Suppl 1:34. [PMID: 33817843 DOI: 10.1111/jgh.15459] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
538 Pandey A, Achrafie L, Kodjamanova P, Tencer T, Kumar J. Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, economic and quality-of-life outcomes. Curr Med Res Opin 2022;:1-40. [PMID: 35608153 DOI: 10.1080/03007995.2022.2081453] [Reference Citation Analysis]
539 Loftus EV Jr, Sands BE, Colombel JF, Dotan I, Khalid JM, Tudor D, Geransar P. Sustained Corticosteroid-Free Clinical Remission During Vedolizumab Maintenance Therapy in Patients with Ulcerative Colitis on Stable Concomitant Corticosteroids During Induction Therapy: A Post Hoc Analysis of GEMINI 1. Clin Exp Gastroenterol 2020;13:211-20. [PMID: 32606883 DOI: 10.2147/CEG.S248597] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]